from evidence to practice in - associazione italiana di ......upper gi upper gi haematology rare...
TRANSCRIPT
1ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
eccocongress.org
FROM EVIDENCE TO PRACTICE IN MULTIDISCIPLINARY CANCER CARE
2 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 3ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
IMPORTANT DEADLINES
Abstract Submission Opens 25 Apr 2016
Early Registration Deadline 27 Jun 2016
Abstract Submission Deadline 25 Aug 2016
Fellowship Application Deadline 30 Aug 2016
Late-Breaking Abstract Submission Opens 23 Nov 2016
Regular Rate Deadline 28 Nov 2016
Late-Breaking Abstract Submission Deadline 7 Dec 2016
ECCO2017 European Cancer Congress 27-30 Jan 2017
Welcome to ECCO2017 – European Cancer Congress, the multidisciplinary evidence based meeting for all cancer types, addressing all oncology disciplines and related healthcare professions. ECCO2017 will have a direct impact on daily clinical practice.
Peter Naredi
President European CanCer Organisation (ECCO)
CHAIR'S INTRODUCTION
Focusing on phase III data, this scientific meeting will put the new evidence into perspective for a multidisciplinary audience by critically reviewing it in expert panels. Leading oncologists will address the value of these potentially practice changing treatments by reviewing their clinical benefits and cost. Experts, patient advocates and the audience will determine whether the data really do support changes in clinical practice.
Recognising the discrepancies between what happens in real life and in a clinical trial setting, the congress will give centre stage to real world data showing the impact on treatment and care.
This focus on clinical practice will give delegates concrete, up-to-date knowledge through a multidisciplinary tumour board format, and give them the opportunity to participate in identifying practice - changing developments.
The Educational Committee has prepared a comprehensive educational programme covering topics from using evidence-based information to guide decisions on treatment options to understanding health economics and outcome research. There will be a strong focus on immunotherapy and personalised medicine.
Based on ground-breaking research, the programme will also look at evolving healthcare systems and the future of cancer treatment, with particular regard to access to innovation, disparities in cancer care and the diminishing oncology workforce. Given the increasing role that primary care looks set to play in secondary cancer care, ECCO2017 will invite community care physicians, oncologists and patient advocates to discuss this evolution.
Regulatory sessions on newly approved drugs and innovation in local regional treatment will gather regulators, HTA bodies, academia, industry and patient advocates.
ECCO2017 will shed light on ECCO policy initiatives, centred around the oncology workforce and quality cancer care, making sure cancer is at the top of the EU public health agenda.
In addition to designing dedicated advocacy sessions, the ECCO Patient Advisory Committee has contributed its essential insights into the scientific programme. During the congress, its members will play a key role in reviewing innovations from the most important perspective – that of the patients they aim to help.
ECCO is an open forum for its members. The first day of ECCO2017 will feature societies’ meetings for their members and the oncology community: the European Oncology Nursing Society (EONS), the European Organisation for Research and Treatment of Cancer (EORTC), the European School of Oncology (ESO), the European Society of Surgical Oncology (ESSO), the European SocieTy for Therapeutic Radiology and Oncology (ESTRO), and the European Society for Paediatric Oncology (SIOPE).
Reaching a global audience, ECCO2017 has an extensive media programme for scientific media worldwide. Submitting your practice changing data for presentation at ECCO2017 will ensure its global visibility.
We thank ECCO member societies, the ECCO Patient Advisory Committee, and leading experts, for designing this innovative scientific programme.
ECCO2017 will change the paradigm of oncology, be part of this change!
Peter Naredi Congress Chair Ian Banks Congress Co-ChairMichael Baumann Scientific Chair Ian Tannock Educational Committee ChairMichel Wouters National Organising Committee Chair
4 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 5ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
ECCO MEMBERS
ECCO represents and serves the interests of over 80 000 professionals in oncology through its 23 Member Organisations. It provides a cohesive platform for European Cancer Societies and Organisations with the aim to work together to improve cancer patient outcomes, and to be the unified voice of the European cancer community when addressing common policy issues.
OFFICIAL MEDIA PARTNERS
The Organising Committee gratefully acknowledges the collaboration and support of our official media partners for the European Cancer Congress ECCO2017:
ACKNOWLEDGEMENTS
ECCO MEMBER SOCIETIES
PRIMARY CARE SESSIONS
The Organising Committee thanks ECCO member societies for their contribution to the development of the ECCO2017 innovative scientific programme.
The Organising Committee gratefully acknowledges the contribution of these organisations to the development of the Primary Care Sessions:
EANO
6 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 7ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
/Disseminating Research/Advancing Care/Improving Lives
Where cancer researchers and oncologists find the latest peer-reviewed research and reviews.A convenient one-stop resource that:• announceslatestArticles-in-PressfromElsevier’scomprehensive portfolioofOncologyjournals• providesaccesstotheneweditionsandarchiveoftheEJCNewsFocusupdates• transmitsfreePodcastsfromleadingpublications• keepsyouinformedonindustrymeetingsandevents• andmuchmore…
Visit OncologyAdvance.com today.ONECLICKACCESSTOESSENTIALRESOURCESINONCOLOGY
CONGRESS COMMITTEES
8 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 9ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
EUROPEAN CANCER CONGRESS 2017 COMMITTEES
SCIENTIFIC MEMBERS
Regina Beets Tan Lifang Liu
Martin Gore Kathy Oliver
Maarten IJzerman Richard Sullivan
Bengt Jönsson Elisabeth de Vries
Valery Lemmens Chris Wild
Yolande Lievens
Michel Wouters – National Organising Chair
Martin van den Bent Kees Punt
Inne Borrel Rinkes Franz Schramel
Guus van Dongen Hermien Schreurs
Hans Gelderblom Ludi Smeele
Koos van der Hoeven Kristien Tytgat
Philip Kluin Marcel Verheij
Jeroen van Moorselaar Michel Versteegh
Hans Nijman Hans de Wilt
Ian Tannock – Educational Committee Chair
Riccardo Audisio Fedro Peccatori
Leticia De Mattos-Arruda Martine Piccart
Jesper Eriksen Rebecca Verity
Dow-Mu Koh
EUROPEAN CANCER CONGRESS 2017 COMMITTEES
NATIONAL ORGANISING COMMITTEE
EDUCATIONAL COMMITTEE
Peter Naredi Congress Chair
Ian Banks Congress Co-Chair
Michael Baumann Scientific Chair
Martine Piccart ECCO Past President
Vincent Gregoire ECCO Treasurer
Michel Wouters National Organising Chair
ORGANISING COMMITTEE
Alain Astier Robert Mansel
Laura Biganzoli Francesco Montorsori
David Cameron Gunnar Sater
Franco Cavalli Martin Schrappe
Leticia De Mattos-Arruda Lena Sharp
Stefan Fanti Martin Taphoorn
Winette van der Graaf Emmanuel Tiret
Santiago Gonzalez-Moreno Luzia Travado
Rüdiger Greinert Vincenzo Valentini
Ilmo Leivo
SCIENTIFIC AND SOCIETY LIAISON COMMITTEE
SOCIETY LIAISON MEMBERS
CONGRESS CORE COMMITTEE
Michael Baumann – Scientific Chair Francesco Montorsi
Ian Banks Peter Naredi
Renzo Canetta Wim Oyen
Elisabeth Eisenhauer Martine Piccart
Daniel Kelly Cornelis van de Velde
Denis Lacombe
10 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 11ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
PROGRAMME OVERVIEW
PR
OG
RA
MM
E O
VE
RV
IEW
LEAD
ERSH
IPPR
OGR
AMM
E I
08:0
0-12
:00
LEAD
ERSH
IPPR
OGR
AMM
E II
14:3
0-17
:00
ESTR
O S
OCI
ETY
PRO
GRAM
ME
SATE
LLIT
E SY
MPO
SIA
ESTR
O S
OCI
ETY
PRO
GRAM
ME
SATE
LLIT
E SY
MPO
SIA
ESTR
O S
OCI
ETY
PRO
GRAM
ME
SATE
LLIT
E SY
MPO
SIA
ESTR
O S
OCI
ETY
PRO
GRAM
ME
SATE
LLIT
E SY
MPO
SIA
EORT
C SO
CIET
YPR
OGR
AMM
E
SATE
LLIT
E SY
MPO
SIA
EORT
C SO
CIET
YPR
OGR
AMM
E
SATE
LLIT
E SY
MPO
SIA
WH
AT A
N O
NCO
LOGI
ST
CAN
LEA
RN F
ROM
AN
IM
AGIN
G SP
ECIA
LIST
SATE
LLIT
E SY
MPO
SIA
TO B
E AN
NO
UN
CED
SATE
LLIT
E SY
MPO
SIA
SIO
PE S
OCI
ETY
PRO
GRAM
ME
SIO
PE S
OCI
ETY
PRO
GRAM
ME
SATE
LLIT
E SY
MPO
SIA
EON
S SO
CIET
YPR
OGR
AMM
E
EON
S SO
CIET
YPR
OGR
AMM
E
SATE
LLIT
E SY
MPO
SIA
ESSO
SO
CIET
YPR
OGR
AMM
E
ESSO
SO
CIET
YPR
OGR
AMM
E
SATE
LLIT
E SY
MPO
SIA
ESSO
SO
CIET
YPR
OGR
AMM
E
ESSO
SO
CIET
YPR
OGR
AMM
E
SATE
LLIT
E SY
MPO
SIA
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(09:
30-1
0:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(11:
00-1
2:00
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(13:
30-1
4:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(16:
30-1
7:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(15:
00-1
6:00
)
FR
IDA
Y 2
7T
H J
AN
UA
RY
20
17
12 13
PR
OG
RA
MM
E O
VE
RV
IEW
SA
TU
RD
AY
28
TH J
AN
UA
RY
20
17
Bre
ast
CN
S E
duca
tion
al L
ymph
oma
Neu
roen
docr
ine
Pri
mar
y Ca
re S
arco
mas
Cha
ngin
g Pr
acti
ce S
essi
on C
olor
ecta
l G
ynae
colo
gy I
ndus
try
Spot
light
ses
sion
s P
allia
tive
Car
e P
oste
r vie
win
g T
hora
cic
Chi
ldho
od C
ance
rs
ECC
O S
essi
on H
ead
and
Nec
k M
elan
oma
Ple
nary
Ses
sion
Sat
ellit
e Sy
mpo
sia
Uro
logy
SU
ND
AY
29
TH J
AN
UA
RY
20
17P
RO
GR
AM
ME
OV
ER
VIE
W
Bre
ast
CN
S E
duca
tion
al L
ymph
oma
Neu
roen
docr
ine
Pri
mar
y Ca
re S
arco
mas
Cha
ngin
g Pr
acti
ce S
essi
on C
olor
ecta
l G
ynae
colo
gy I
ndus
try
Spot
light
ses
sion
s P
allia
tive
Car
e P
oste
r vie
win
g T
hora
cic
Chi
ldho
od C
ance
rs
ECC
O S
essi
on H
ead
and
Nec
k M
elan
oma
Ple
nary
Ses
sion
Sat
ellit
e Sy
mpo
sia
Uro
logy
Upp
er G
I H
aem
atol
ogy
Rare
Can
cers
Upp
er G
I H
aem
atol
ogy
Rare
Can
cers
CEN
TRAL
NER
VOU
SSY
STEM
CLIN
ICAL
SYM
POSI
UM
Glio
ma
and
Im
mun
othe
rapy
10:1
5-11
:15
CHAN
GIN
G PR
ACTI
CE
SESS
ION
Use
of E
lect
roni
c To
ols
and
Tele
med
icin
e in
O
ncol
ogy:
"The
Doc
tor
Will
Sky
pe Y
ou N
ow"
11:3
0-12
:45
POLI
CY S
ESSI
ON
II
Mee
ting
the
Chal
leng
es o
f Cr
oss-
Bord
er C
ance
r Car
e 13
:15-
14:4
5
EDU
CATI
ON
AL S
ESSI
ON
PR
OGR
AMM
E
Impr
ovin
g Pa
tien
t Saf
ety
in
Onc
olog
y15
:00-
16:3
0
CEN
TRAL
NER
VOU
SSY
STEM
CRIT
ICAL
REV
IEW
SES
SIO
NCr
itic
al R
evie
w o
f Pr
esen
ted
Tria
ls a
nd
Impl
icat
ion
in P
ract
ice
16:4
5-18
:15
SATE
LLIT
E SY
MPO
SIA
PATI
ENT
INVO
LVEM
ENT
IN
REG
ULA
TORY
DIS
CUSS
ION
S
Patie
nt In
volv
emen
t in
Regu
lato
ry D
iscu
ssio
ns
07:4
5-08
:45
CH
ANGI
NG
PRAC
TICE
SE
SSIO
N
The
Valu
e of
Can
cer R
egis
trie
s11
:30-
12:4
5
SATE
LLIT
E SY
MPO
SIA
EDU
CATI
ON
AL S
ESSI
ON
Real
Wor
ld D
ata:
Hea
lth
Out
com
es R
esea
rch
(Rep
eate
d)15
:00-
16:3
0
HAE
MAT
OLO
GY
CRI
TICA
L RE
VIEW
SES
SIO
NRe
view
of P
rese
nted
Tr
ials
and
Impl
icat
ion
in
Pra
ctic
e16
:45-
18:1
5
SATE
LLIT
E SY
MPO
SIA
NEU
ROEN
DO
CRIN
E TU
MO
URS
- RA
RE C
ANCE
RS
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
PALL
IATI
VE A
ND
SU
PPO
RTIV
E CA
RE
CLIN
ICAL
SYM
POSI
UM
Tria
ls &
Out
com
e Re
sear
ch
that
Cha
nge
Prac
tice
10:1
5-11
:15
JOIN
T EC
CO-A
SCO
SE
SSIO
N
TOPI
C TB
A11
:30-
12:4
5
SATE
LLIT
E SY
MPO
SIA
CHIL
DH
OO
DCA
NCE
RS
CLIN
ICAL
SYM
POSI
UM
Tr
ansl
atio
nal A
ppro
ache
s in
Pa
edia
tric
Onc
olog
y15
:00-
16:3
0
CHIL
DH
OO
DCA
NCE
RS
CRIT
ICAL
REV
IEW
SES
SIO
NCr
itic
al R
evie
w o
f Pr
esen
ted
Tria
ls a
nd
Impl
icat
ion
in P
ract
ice
16:4
5-18
:15
SATE
LLIT
E SY
MPO
SIA
THO
RACI
C CA
NCE
R
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
PLEN
ARY
SESS
ION
PRAC
TICE
CH
ANGI
NG
TRIA
LS II
09:0
0-11
:00
THO
RACI
C CA
NCE
R
CLIN
ICAL
SYM
POSI
UM
Tria
ls &
Out
com
e Re
sear
ch
that
Cha
nge
Prac
tice
10:1
5-11
:15
CHAN
GIN
G PR
ACTI
CE
SESS
ION
Reim
burs
emen
t and
M
arke
t Acc
ess
to
Inno
vati
ve O
ncol
ogy
Trea
tmen
ts11
:30-
13:0
0
BREA
ST C
ANCE
R
PRO
FFER
ED P
APER
S15
:00-
16:3
0
BREA
ST C
ANCE
R
CRIT
ICAL
REV
IEW
SES
SIO
N
Criti
cal R
evie
w o
f Pre
sent
ed
Tria
ls a
nd Im
plic
atio
n in
Pr
actic
e16
:45-
18:1
5
URO
LOG
Y
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
URO
LOG
Y
CLIN
ICAL
SYM
POSI
UM
Blad
der C
ance
r10
:15-
11:1
5
CHAN
GIN
G PR
ACTI
CE
SESS
ION
Not
Eve
ry C
ance
r Cen
tre
Shou
ld T
reat
Eve
ry
Canc
er P
atie
nt. W
hat's
th
e Ev
iden
ce?
11:3
0-12
:45
SATE
LLIT
E SY
MPO
SIA
COLO
RECT
AL C
ANCE
R
PRO
FFER
ED P
APER
S15
:00-
16:3
0
COLO
RECT
AL C
ANCE
R
CRIT
ICAL
REV
IEW
SES
SIO
NCr
itic
al R
evie
w o
f Pr
esen
ted
Tria
ls a
nd
Impl
icat
ion
in P
ract
ice
16:4
5-18
:15
SATE
LLIT
E SY
MPO
SIA
GYN
AECO
LOG
Y
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
EDU
CATI
ON
ALIM
MER
SIO
N
PRO
GRAM
ME
Intr
oduc
tion
to
Imm
unot
hera
py a
nd
the
Scie
nce
Behi
nd it
(N
ovic
e)
11:1
5-12
:45
SATE
LLIT
E SY
MPO
SIA
EDU
CATI
ON
AL IM
MER
SIO
N
PRO
GRAM
ME
Adva
nced
Cou
rse
in
Imm
unol
ogy
and
Imm
unot
hera
py
(Adv
ance
d)15
:00-
17:3
0
SATE
LLIT
E SY
MPO
SIA
UPP
ER G
I - H
EPAT
OBI
LLAR
Y
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
UPP
ER G
I CAN
CER
CLIN
ICAL
SYM
POSI
UM
Tria
ls &
Out
com
e Re
sear
ch
that
Cha
nge
Prac
tice
10:1
5-11
:15
EDU
CATI
ON
AL S
ESSI
ON
Pati
ent R
epor
ted
Out
com
es11
:30-
13:0
0
CHAN
GIN
G PR
ACTI
CE
SESS
ION
Va
lue
in O
ncol
ogy
Care
13:1
5-14
:30
MEL
ANO
MA
PRO
FFER
ED P
APER
S15
:00-
16:3
0
MEL
ANO
MA
CRIT
ICAL
REV
IEW
SES
SIO
NCr
itic
al R
evie
w o
f Pr
esen
ted
Tria
ls a
nd
Impl
icat
ion
in P
ract
ice
16:4
5-18
:15
SATE
LLIT
E SY
MPO
SIA
PATI
ENT
ADVO
CACY
SE
SSIO
N
Side
Effe
cts:
Out
of
Sigh
t Out
of M
ind
10:1
5-11
:15
SATE
LLIT
E SY
MPO
SIA
PATI
ENT
ADVO
CACY
SE
SSIO
N
Tran
slat
ing
Rese
arch
into
Pa
tient
Val
ue15
:00-
16:3
0
PATI
ENT
ADVO
CACY
SE
SSIO
N
Cont
rove
rsie
s in
Care
- M
yths
and
Rea
litie
s16
:45-
18:1
5
SATE
LLIT
E SY
MPO
SIA
POST
ERS
POST
ER V
IEW
ING
(12:
00-1
4:00
)
POST
ERS
POST
ER V
IEW
ING
(16:
00-1
8:00
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(09:
30-1
0:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(11:
00-1
2:00
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(13:
30-1
4:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(16:
30-1
7:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(15:
00-1
6:00
)
EDU
CATI
ON
AL S
ESSI
ON
Acqu
irin
g Pr
acti
cal S
kills
: D
esig
ning
Pro
ject
s,
Effe
ctiv
enes
s in
Wri
ting
, Fu
ndin
g Yo
ur R
esea
rch
and
Spea
king
10:1
5-12
:15
SATE
LLIT
E SY
MPO
SIA
EDU
CATI
ON
AL S
ESSI
ON
How
to E
ffici
entl
y ru
n a
Tum
our B
oard
(rep
eate
d)07
:45-
08:4
5
EDU
CATI
ON
AL S
ESSI
ON
Can
we
Affo
rd it
? H
ow to
Det
erm
ine
Cost
Ef
fect
iven
ess (
Repe
ated
)10
:15-
11:4
5
SATE
LLIT
E SY
MPO
SIA
PALL
IATI
VE A
ND
SU
PPO
RTIV
E CA
RE
PRO
FFER
ED P
APER
S15
:00-
16:3
0
PALL
IATI
VE A
ND
SU
PPO
RTIV
E CA
RE
CRIT
ICAL
REV
IEW
SES
SIO
NCr
itic
al R
evie
w o
f Pr
esen
ted
Tria
ls a
nd
Impl
icat
ion
in P
ract
ice
16:4
5-18
:15
SATE
LLIT
E SY
MPO
SIA
LUN
CH
12:4
5 - 1
4:45
HEA
D &
NEC
K CA
NCE
R
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
HEA
D &
NEC
K CA
NCE
R
CLIN
ICAL
SYM
POSI
UM
Tria
ls &
Out
com
e Re
sear
ch
that
Cha
nge
Prac
tice
10:1
5-11
:15
EDU
CATI
ON
AL S
ESSI
ON
Canc
er Im
agin
g: A
Key
Co
mpo
nent
of
Pers
onal
ised
Onc
olog
y 11
:30-
13:0
0
CHAN
GIN
G PR
ACTI
CE
SESS
ION
Yes,
Dat
a Ca
n Ta
lk
Toge
ther
13.1
5-14
:45
HEA
D &
NEC
K CA
NCE
R
PRO
FFER
ED P
APER
S15
:00-
16:3
0
HEA
D &
NEC
K CA
NCE
R
CRIT
ICAL
REV
IEW
SES
SIO
NCr
itic
al R
evie
w o
f Pr
esen
ted
Tria
ls a
nd
Impl
icat
ion
in P
ract
ice
16:4
5-18
:15
SATE
LLIT
E SY
MPO
SIA
EDU
CATI
ON
AL S
ESSI
ON
How
to e
ffici
entl
y ru
na
Tum
our B
oard
07:4
5-08
:45
CE
NTR
AL N
ERVO
US
SYST
EM
CLIN
ICAL
SYM
POSI
UM
Brai
n M
etas
tase
s10
:15-
11:1
5
EMA
AND
HTA
S
REGU
LATO
RY S
ESSI
ON
EMA
and
HTA
s on
the
Hot
Sea
t11
:30-
12:4
5
SATE
LLIT
E SY
MPO
SIA
CLIN
ICAL
SYM
POSI
UM
CNS/
CHIL
DH
OO
DCA
NCE
RS
15:0
0-16
:00
REG
ULA
TORY
SES
SIO
N
Case
Stu
dies
in
Appr
oval
s of
Tar
gete
d Ag
ents
: Sin
gle-
Arm
Tri
als
16:1
0 - 1
7:10
REG
ULA
TORY
SES
SIO
N
Real
-life
Impl
emen
tati
on
of B
iom
arke
r Inf
orm
atio
n to
Info
rm T
reat
men
t and
Re
gula
tory
Dec
isio
ns -
the
PD-L
1 Ex
peri
ence
17:1
5-18
:15
CEN
TRAL
NER
VOU
SSY
STEM
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
EDU
CATI
ON
ALIM
MER
SIO
N
PRO
GRAM
ME
Intr
oduc
tion
to O
mic
san
d Pe
rson
alis
ed
Med
icin
e (N
ovic
e)10
:15-
11:4
5
POLI
CY S
ESSI
ON
I
How
can
Onc
opol
icy
Stre
ngth
en
Mul
tidi
scip
linar
y Pr
acti
ce?
13:1
5-14
:45
EDU
CATI
ON
AL
IMM
ERSI
ON
PR
OGR
AMM
E
Pers
onal
ised
M
edic
ine:
Fro
m
Gen
omic
s to
Clin
ical
Pr
acti
ce (A
dvan
ced)
15:4
5-18
:15
SATE
LLIT
E SY
MPO
SIA
BREA
ST C
ANCE
R I
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
PLEN
ARY
SESS
ION
PRAC
TICE
CH
ANGI
NG
TRIA
LS I
09:0
0-10
:00
BREA
ST C
ANCE
R
CLIN
ICAL
SYM
POSI
UM
Tria
ls &
Out
com
e Re
sear
ch
that
Cha
nge
Prac
tice
10:1
5-11
:15
EDU
CATI
ON
AL S
ESSI
ON
Real
Wor
ld D
ata:
H
ealt
h O
utco
mes
Re
sear
ch11
:30-
13:0
0
THO
RACI
C CA
NCE
R
PRO
FFER
ED P
APER
S15
:00-
16:3
0
HO
T D
EBAT
E
TOPI
C TB
A
16:4
5-17
:45
RECT
AL C
ANCE
R
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
COLO
RECT
AL C
ANCE
R
CLIN
ICAL
SYM
POSI
UM
Tria
ls &
Out
com
e Re
sear
ch
that
Cha
nge
Prac
tice
10:1
5-11
:15
CHAN
GIN
G PR
ACTI
CE
SESS
ION
Affo
rdab
ility
of
Inno
vati
on in
Can
cer
Care
: How
to B
end
the
Cost
Cur
ve in
an
Era
of
Tech
nolo
gy E
volu
tion
11:3
0-12
:45
SATE
LLIT
E SY
MPO
SIA
URO
LOG
Y
PRO
FFER
ED P
APER
S15
:00-
16:3
0
EDU
CATI
ON
AL S
ESSI
ON
Tom
orro
w's
Clin
ical
/ Pr
acti
cal A
pplic
atio
ns
of L
iqui
d Bi
opsy
16:4
5-18
15
SATE
LLIT
E SY
MPO
SIA
MEL
ANO
MA
CLIN
ICAL
SYM
POSI
UM
Tria
ls &
Out
com
e Re
sear
ch
that
Cha
nge
Prac
tice
10:1
5-11
:15
JOIN
T EC
CO-J
SCO
SESS
ION
TOPI
C TB
A11
:30-
12:4
5
SATE
LLIT
E SY
MPO
SIA
ECCO
SES
SIO
N
Qua
lity
Canc
er C
are
Indi
cato
rs
15:0
0-16
:30
GYN
AECO
LOGI
CAL C
ANCE
R -
EARL
Y CE
RVIC
AL C
ANCE
R
CLIN
ICAL
SYM
POSI
UM
Inno
vati
ve S
urge
ry V
ersu
s In
nova
tive
Rad
ioth
erap
y16
:45-
18:1
5
SATE
LLIT
E SY
MPO
SIA
PALL
IATI
VE
& S
UPP
ORT
IVE
CARE
MD
TU
MO
UR
BOAR
DEn
d of
life
07:4
5-08
:45
EDU
CATI
ON
AL S
ESSI
ON
Can
we
Affo
rd it
? H
ow to
Det
erm
ine
Cost
Eff
ecti
vene
ss10
:15-
11:4
5
SATE
LLIT
E SY
MPO
SIA
EDU
CATI
ON
AL S
ESSI
ON
Evid
ence
-bas
edM
anag
emen
t of C
ance
rin
Old
er P
atie
nts
16:1
5-18
:15
SATE
LLIT
E SY
MPO
SIA
POST
ERS
POST
ER V
IEW
ING
(12:
00-1
4:00
)
POST
ERS
POST
ER V
IEW
ING
(16:
00-1
8:00
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(09:
30-1
0:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(11:
00-1
2:00
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(13:
30-1
4:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(16:
30-1
7:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(15:
00-1
6:00
)
LYM
PHO
MA
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
PRI
MAR
Y CA
RE S
ESSI
ON
The
Expa
ndin
g Ro
le
of P
rim
ary
Care
in
Canc
er M
anag
emen
t10
:15-
11:1
5
PRIM
ARY
CARE
SES
SIO
N
Dia
gnos
ing
Canc
er
Earl
y - T
he M
ost E
ffec
tive
St
rate
gy to
Impr
ove
Surv
ival
: Cur
rent
Issu
es in
Sc
reen
ing
and
Dia
gnos
is11
:30-
12:4
5
SATE
LLIT
E SY
MPO
SIA
PRIM
ARY
CARE
SES
SIO
N
Trea
tmen
t and
M
anag
emen
t of C
ance
r Pa
tien
ts &
Sur
vivo
rs :
the
need
for j
oine
d-up
ap
proa
ches
15:0
0-16
:30
PRIM
ARY
CARE
SES
SIO
N
Inte
grat
ed M
odel
s of
Ca
ncer
Man
agem
ent:
Brin
ging
Pri
mar
y Ca
re a
nd
Seco
ndar
y Ca
re T
oget
her
16:4
5-18
:15
SATE
LLIT
E SY
MPO
SIA
CHIL
DH
OO
D C
ANCE
RS I
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
NEU
ROEN
DO
CRIN
E TU
MO
URS
CLIN
ICAL
SYM
POSI
UM
10:1
5-11
:15
EDU
CATI
ON
AL S
ESSI
ON
Reco
gnis
ing
and
Man
agin
g Et
hica
l Ch
alle
nges
in
Canc
er C
are
11:3
0-13
:00
SATE
LLIT
E SY
MPO
SIA
RARE
CAN
CERS
-
SARC
OM
AS
PRO
FFER
ED P
APER
S15
:00-
16:3
0
RARE
CAN
CERS
-
SARC
OM
AS
CLIN
ICAL
SYM
POSI
UM
16:4
5-18
:15
SATE
LLIT
E SY
MPO
SIA
LUN
CH
12:4
5 - 1
4:45
LUN
CH
12:4
5 - 1
4:45
14 15ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
MULTIDISCIPLINARY TUMOUR BOARD SESSION
Case presentation discussed by a multidisciplinary board, with interaction of the audience. An expert moderator leads the session presenting common cases.
PLENARY SESSION
Presentations of the new and late breaking practice changing data representing the four pillars of the programme.
CLINICAL SYMPOSIUM
Presentations of key practice changing trials and real world data, it can be new data or presented in the last 12 months (which will be updated, if applicable).
CHANGING PRACTICE SESSION
These sessions discuss the organisation of cancer services for the future, the health economics of cancer treatment and methodologies for outcome research.
PROFFERED PAPER SESSION
Oral presentations of the best and new late breaking abstracts and optionally also including invited speaker abstracts on key practice changing data and outcome research.
POSTER SESSION
Presentations in poster format of selected abstracts based on the four pillars of the programme.
ECCO2017 SESSION TYPES
CRITICAL REVIEW SESSION
Critical review of the trials presented in the plenary session, clinical symposia and proffered papers. Experts from different disciplines will give an overview of the implications for practice. In addition, one top expert will question and define the value of these new treatments in a multidisciplinary context. The session will host a roundtable discussion with a panel and audience; ending with interaction with the audience on whether they agree with the panel.
PATIENT ADVOCATE PROGRAMME
Sessions discussing topics that influence cancer care. These sessions are open to all delegates.
EDUCATIONAL IMMERSION PROGRAMME – NOVICE LEVEL/ADVANCED LEVEL
This course is aimed at audiences with either novel or advanced knowledge, giving in-depth education on two hot topics. Participants can also follow both basic and advanced level sessions to get high immersion into the topic.
EDUCATIONAL SESSION
State of the art lectures on topics that impact on daily practice and giving knowledge on health economics and outcome research.
POLICY SESSION
Presenting and discussing ECCO activities related to policy.
PRIMARY CARE PROGRAMME
Programme devised for primary care physicians and the oncology community to discuss topics related to primary care involvement in cancer care.
PR
OG
RA
MM
E O
VE
RV
IEW
UPP
ER G
I
MD
TU
MO
UR
BOAR
DO
esop
hage
al C
ance
r 07
:45-
08:4
5
CHAN
GIN
G PR
ACTI
CESE
SSIO
N
Equi
ty in
Can
cer C
are:
St
ill a
Lon
g W
ay to
Go
09:0
0-10
:00
EDU
CATI
ON
AL S
ESSI
ON
Evid
ence
-Bas
ed P
ublic
H
ealt
h In
terv
enti
ons
to
Prev
ent C
ance
r10
:15-
11:4
5
SATE
LLIT
E SY
MPO
SIA
REGU
LATO
RY S
ESSI
ON
Regu
lati
ng In
nova
tion
in
Loca
l Reg
iona
l Tre
atm
ent
09:0
0-11
:00
TIM
E FO
R
SATE
LLIT
E SY
MPO
SIA
EDU
CATI
ON
AL S
ESSI
ON
Inef
ficie
ncie
s in
Can
cer
Care
09:0
0-10
:30
BREA
ST C
ANCE
R II
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
CLIN
ICAL
SYM
POSI
UM
G
ENER
AL
Man
agin
gO
ligom
etas
tati
cD
isea
se09
:00-
10:0
0
THO
RACI
C CA
NCE
R
CRIT
ICAL
REV
IEW
SES
SIO
N
Crit
ical
Rev
iew
of
Pres
ente
d Tr
ials
and
Im
plic
atio
n in
Pra
ctic
e10
:15-
11:4
5
PLEN
ARY
SESS
ION
Prac
tice
Cha
ngin
g Tr
ials
III
12:0
0-13
:00
COLO
N C
ANCE
R
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
CHAN
GIN
G PR
ACTI
CESE
SSIO
N
Lung
Can
cer
Scre
enin
g: C
an W
eAf
ford
Not
to?
09:0
0-10
:00
URO
LOG
Y
CRIT
ICAL
REV
IEW
SES
SIO
NCr
itic
al R
evie
w o
f Pr
esen
ted
Tria
ls a
nd
Impl
icat
ion
in P
ract
ice
10:1
5-11
:45
RESE
RVED
TIM
E
SATE
LLIT
E SY
MPO
SIA
EDU
CATI
ON
AL S
ESSI
ON
Reco
gnis
ing
and
Avoi
ding
Bia
s in
Cl
inic
al T
rial
s08
:30-
10:0
0
CHAN
GIN
G PR
ACTI
CE
SESS
ION
Exte
rnal
Val
idit
y of
Cl
inic
al T
rial
s10
:15-
11:1
5
SATE
LLIT
E SY
MPO
SIA
OLI
GIO
MET
ASTA
TIC
DIS
EASE
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
PRO
FFER
ED P
APER
S
Upp
er G
I Can
cer
09:0
0-10
:15
UPP
ER G
I
CRIT
ICAL
REV
IEW
SES
SIO
NCr
itic
al R
evie
w o
f Pr
esen
ted
Tria
ls a
nd
Impl
icat
ion
in P
ract
ice
10:3
0-11
:45
CHIL
DH
OO
D C
ANCE
RS II
MD
TU
MO
UR
BOAR
D07
:45-
08:4
5
EDU
CATI
ON
AL S
ESSI
ON
Prac
tici
ng O
ncol
ogy
in
Coun
trie
s w
ith
Lim
ited
Re
sour
ces
09:0
0-10
:30
SATE
LLIT
ES
SATE
LLIT
E SY
MPO
SIA
Post
ers
POST
ER V
IEW
ING
(12:
30-1
4:30
)
PALL
IATI
VE A
ND
SU
PPO
RTIV
E CA
RE
MD
TU
MO
UR
BOAR
DPa
lliat
ive
and
Supp
orti
ve
Care
- El
derl
y07
:45-
08:4
5
WO
RKSH
OP
The
Art o
f Des
igni
ng
Clin
ical
Tri
als:
The
Lat
est i
n M
etho
ds in
Clin
ical
Canc
er R
esea
rch
09:0
0-12
:00 RE
SERV
ED
SATE
LLIT
E SY
MPO
SIA
CLIN
ICAL
TRI
ALS
INVE
STIG
ATO
R'S
MEE
TIN
GS
Bre
ast
CN
S E
duca
tion
al L
ymph
oma
Neu
roen
docr
ine
Pri
mar
y Ca
re S
arco
mas
Cha
ngin
g Pr
acti
ce S
essi
on C
olor
ecta
l G
ynae
colo
gy I
ndus
try
Spot
light
ses
sion
s P
allia
tive
Car
e P
oste
r vie
win
g T
hora
cic
Chi
ldho
od C
ance
rs
ECC
O S
essi
on H
ead
and
Nec
k M
elan
oma
Ple
nary
Ses
sion
Sat
ellit
e Sy
mpo
sia
Uro
logy
Upp
er G
I H
aem
atol
ogy
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(09:
30-1
0:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(13:
30-1
4:30
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
(15:
00-1
6:00
)
IND
UST
RY S
POTL
IGH
T SE
SSIO
NS
MO
ND
AY
30
TH J
AN
UA
RY
20
17
Rare
Can
cers
16 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 17ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
GENERAL SESSIONSGENERAL SESSIONS
SATURDAY 28 JANUARY 2017
09:00 - 10:00
Plenary Session: Practice Changing Trials I Best and late-breaking oral abstracts to be announced in the online searchable programme as soon as possible
11:30 - 12:45
Joint Session: ECCO-JSCO Joint Session
Details to be announced in the online searchable programme as soon as possible
15:00 - 16:30
ECCO Session: Quality Cancer Care Indicators
Details to be announced in the online searchable programme as soon as possible
SUNDAY 29 JANUARY 2017
09:00 - 10:00
Plenary Session: Practice Changing Trials II
Best and late-breaking oral abstracts to be announced in the online searchable programme as soon as possible
11:30 - 12:45
Joint Session: Joint ECCO-ASCO Session
Details to be announced in the online searchable programme as soon as possible
MONDAY 30 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Oligometastatic Disease
Case presentation
Moderator: M. Guckenberger (Switzerland)
GI Surgeon Panel: P. Piso (Germany)
Radiation oncologist Panel: J. Widder (Netherlands)
Thoracic surgeon Panel: I. Schmitt-Opitz (Switzerland)
Radiologist To be announced
Medical oncologist Panel: C.J.A. Punt (Netherlands)
Nuclear medicine physician Panel: A. Chiti (Italy)
Oncology nurse To be announced
09:00 - 10:00
Clinical Symposium: Managing Oligometastatic Disease Chair: M. Guckenberger (Switzerland)
Chair: T. Gruenberger (Austria)
Peri-operative chemotherapy in patients with resectable colorectal liver metastases - lessons learned from the New EPOC trial Speaker: J. Primrose (United Kingdom)
Salvage treatment or active clinical surveillance for oligometastatic prostate cancer: A randomised Phase II Trial Speaker: G. De Meerleer (Belgium)
Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer: A randomised Phase III Trial Speaker: D. Landau (United Kingdom)
Phase I clinical study combining L19-IL2 with stereotactic ablative body radiotherapy in patients with oligometastatic solid tumour Speaker: P. Lambin (Netherlands)
GENERAL SESSIONS
09:00 - 12:00
Workshop: The Art of Designing Clinical Trials: The Latest in Methods in Clinical Cancer Research
Chair: S. Sleijfer (Netherlands)
Chair: L. De Mattos-Arruda (Spain)
Introductory remarks Speaker: L. De Mattos-Arruda (Spain)
ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research: A platform to learn the essentials of good clinical trial design Speaker: S. Sleijfer (Netherlands)
Challenges faced by young oncologists executing clinical trials
The Flims Alumni Club Speaker: L. De Mattos-Arruda (Spain)
Surgical oncologist’s perspective Speaker: J.R. Van der Vorst (Netherlands)
Medical oncologist’s perspective Speaker: B. Sousa (Portugal)
Designing a clinical trial to improve cancer medicine: Questions you must ask Speaker: L.L. Siu (Canada)
Expert exchange: Hot topics in cancer clinical trials Genotype-based clinical trials Speaker: J.C. Soria (France)
Assessing anti-tumour activity of immunotherapeutic agents Speaker: J.B.A.G. Haanen (Netherlands)
Clinically relevant differences of new oncology treatments: What to aim for? Speaker: M. Piccart (Belgium)
Expert panel: Assess and evaluate cancer clinical trial concepts Medical Oncologist Panel: S. Sleijfer (Netherlands)
Medical Oncologist Panel: L.L. Siu (Canada)
Statistician Panel: J. Bogaerts (Belgium)
Trial concept presentation 1 Speaker: To be announced
Panel discussion Trial concept presentation 2 Speaker: To be announced
Panel discussion
Trial concept presentation 3 Speaker: To be announced
Panel discussion
Concluding remarks Speaker: S. Sleijfer (Netherlands)
12:00 - 13:00
Plenary Session: Practice Changing Trials III
Best and late-breaking oral abstracts to be announced in the online searchable programme as soon as possible
18 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 19ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
GENERAL SESSIONS GENERAL SESSIONSBREAST CANCER
SATURDAY 28 JANUARY 2017
07.45 - 08:45 Multidisciplinary Tumour Board: Breast Cancer I
Case presentation: Management of the axilla Moderator: I.T. Rubio (Spain)
Surgical oncologist Panel: J. Van der Hage (Netherlands)
Medical oncologist Panel: P. Conte (Italy)
Radiation oncologist Panel: C.E. Coles (United Kingdom)
Imaging specialist Panel: F. Sardanelli (Italy)
Pathologist Panel: G. Cserni (Hungary)
Oncology nurse Panel: D. Van der Meer (Netherlands)
10.15 - 11:15
Clinical Symposium: Breast Cancer Trials and Outcome Research that Change Practice
Chair: B. Offersen (Denmark)
Chair: P. Conte (Italy)
MINDACT TrialSpeaker: M. Piccart (Belgium)
ESME HER 2 +ve TrialSpeaker: S. Delaloge (France)
Partial irradiation: GEC-ESTRO TrialSpeaker: V. Strnad (Germany)
Partial irradiation: Import LOW TrialSpeaker: C.E. Coles (United Kingdom)
SUNDAY 29 JANUARY 2017
15:00 - 16.30
Proffered Papers: Breast Cancer
Presentation of Selected Abstracts
16:45 - 18:15
Critical Review: Breast Cancer - Critical Review of Presented Trials and Implication in Practice
Chair: O. Pagani (Switzerland)
Chair: To be announced
Medical oncology perspectiveSpeaker: M. Piccart (Belgium)
Radiation oncology perspectiveSpeaker: J.R. Yarnold (United Kingdom)
Surgical oncology perspectiveSpeaker: L. Wyld (United Kingdom)
What is the value of these new treatments?Speaker: To be announced
Panel DiscussionMedical oncologistPanel: M. Piccart (Belgium)
Radiation oncologistPanel: J.R. Yarnold (United Kingdom)
Surgical oncologistPanel: L. Wyld (United Kingdom)
Oncology nursePanel: Y. Wengström (Sweden)
Patient advocatePanel: To be announced
MONDAY 30 JANUARY 2017
07:45 - 08.45
Multidisciplinary Tumour Board: Breast Cancer II
Case presentation: Are there limits to breast conservation?Moderator: E.J.T. Rutgers (Netherlands)
Surgical oncologistPanel: O. Gentilini (Italy)
Medical oncologistPanel: D.A. Cameron (United Kingdom)
Radiation oncologistPanel: B. Cutuli (France)
Imaging specialistPanel: P. Steyerova (Czech Republic)
Clinical geneticistPanel: N. Hoogerbrugge (Netherlands)Oncology nursePanel: D. Fenlon (United Kingdom)
CENTRAL NERVOUS SYSTEM
SATURDAY 28 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Central Nervous System
Case presentation: Low-grade glioma patientModerator: M.J.B Taphoorn (Netherlands)
NeurosurgeonPanel: To be announced
Radiation oncologistPanel: B. Baumert (Germany)
Neuro oncologistPanel: M.J. Van den Bent (Netherlands)
Paediatric oncologistPanel: To be announced
Oncology nursePanel: H. Zwinkels - van vliet (Netherlands)
10:15 - 11:15
Clinical Symposium: Central Nervous System - Brain Metastases
Chair: M. Brada (United Kingdom)
Targeted agents in brain metastasesSpeaker: To be announced
Stereotactic radiosurgerySpeaker: G. Minniti (Italy)
Hippocampal avoidance IMRTSpeaker: D.C. Weber (Switzerland)
Title: To be announcedSpeaker: To be announced
15:00 - 16:00
Clinical Symposium: CNS/Childhood Cancers
Chair: M.J. Van den Bent (Netherlands)
MedulloblastomaSpeaker: To be announced
Tumour biologySpeaker: S. Pfister (Germany)
High grade gliomaSpeaker: D. Hargrave (United Kingdom)
EpendyomaSpeaker: D. Frappaz (France)
SUNDAY 29 JANUARY 2017
10:15 - 11:15
Clinical Symposium: Central Nervous System - Glioma and Immunotherapy
Chair: M. Weller (Switzerland)
Chair: W. Wick (Germany)
Immunotherapy/EGFRviiiSpeaker: M. Weller (Switzerland)
EORTC 26053 CATNONSpeaker: M.J. Van den Bent (Netherlands)
EORTC 26033 Low-grade gliomaSpeaker: B. Baumert (Germany)
Tumour treating fieldsSpeaker: R. Stupp (Switzerland)
16:45 - 18:15
Critical Review: Central Nervous System - Critical Review of Presented Trials and Implication in Practice
Chair: P. Wen (USA)
Chair: K. Oliver (United Kingdom)
NeurologySpeaker: W. Wick (Germany)
RadiotherapySpeaker: M. Krause (Germany)
NeurosurgerySpeaker: To be announced
What is the value of these new treatments?Speaker: P. Wen (USA)
Panel Discussion
NeurologyPanel: W. Wick (Germany)
RadiotherapyPanel: M. Krause (Germany)
NeurosurgeryPanel: To be announced
Oncology nursingPanel: To be announced
Patient advocacyPanel: K. Oliver (United Kingdom)
20 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 21ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
GENERAL SESSIONS GENERAL SESSIONSCHILDHOOD CANCERS
SATURDAY 28 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Childhood Cancers I
Case presentation: Brain tumoursModerator: To be announced
Paediatric oncologistPanel: F. Doz (France)
Radiation oncologistPanel: T. Boterberg (Belgium)
Paediatric oncologistPanel: R. Riccardi (Italy)
Paediatric oncologistPanel: L.J. Hjorth (Sweden) Adult oncologistPanel: D. Frappaz (France) Oncology NursePanel: To be announced
SUNDAY 29 JANUARY 2017
15:00 - 16:30
Clinical Symposium: Childhood Cancers - Translational Approaches in Paediatric Oncology
Chair: M. Schrappe (Germany)
Chair: G. Vassal (France)
Introduction - Translation from pathway to clinical practice Speaker: P. Kearns (United Kingdom)
Therapeutic translation of novel biological findings in neuroblastoma Speaker: R. Ladenstein (Austria)
Introduction of novel classes of therapeutics in haematological malignancies Speaker: A. Von Stackelberg (Germany)
Integrated approaches in malignant lymphoma Speaker: C. Patte (France)
Liver tumours: Novel clinical research through transfer of expert advice in an European effort Speaker: B.J. Morland (United Kingdom)
Discussion
16:45 - 18:15
Critical Review: Childhood Cancers - Sarcomas - Critical Review of Presented Trials and Implication in Practice
Chair: S. Bielack (Germany)
IntroductionSpeaker: L. Brugieres (France)
Medical oncology approaches to paediatric type sarcomasSpeaker: To be announced
Paediatric oncology approaches to adult type sarcomasSpeaker: A. Ferrari (Italy)
Paediatric surgerySpeaker: To be announced
Proton therapySpeaker: M. Krause (Germany)
What is the value of these new treatments?Speaker: B.J. Morland (United Kingdom)
Medical oncologistPanel: To be announced
Paediatric oncologistPanel: A. Ferrari (Italy)
Paediatric surgeonPanel: To be announced
Radiation oncologistPanel: M. Krause (Germany)
MONDAY 30 JANUARY 2017
07:45 - 08:45
Childhood Cancers
Multidisciplinary Tumour Board: Childhood Cancers II
Case presentation: Leukaemia Moderator: M. Schrappe (Germany)
Paediatric oncologistPanel: J. Stary (Czech Republic)
Paediatric oncologistPanel: A. Biondi (Italy)
Adult oncologistPanel: To be announced
ImmunologistPanel: To be announced
Oncology NursePanel: C. Freidank (Germany)
COLORECTAL CANCER
SATURDAY 28 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Rectal Cancer
Case presentationModerator: V. Valentini (Italy)
Surgical oncologistPanel: E. Angenete (Sweden)
Medical oncologistPanel: C.J.A. Punt (Netherlands)
Radiation oncologistPanel: C. Rödel (Germany)
Imaging specialistPanel: R.G.H. Beets-Tan (Netherlands)
PathologistPanel: P. Quirke (United Kingdom)
Oncology nursePanel: C. Taylor (United Kingdom)
10:15 - 11:15
Clinical Symposium: Colorectal Cancer - Trials and Outcome Research that Change Practice
Chair: C.J.A. Punt (Netherlands)
Chair: K. Haustermans (Belgium)
PRODIGE 7 TrialSpeaker: F. Quenet (France)
FOXTROT TrialSpeaker: D. Morton (United Kingdom)
Rapido TrialSpeaker: C. Marijnen (Netherlands)
5x5 plus chemo TrialSpeaker: K. Bujko (Poland)
SUNDAY 29 JANUARY 2017
15:00 - 16:30
Proffered Papers: Colorectal CancerPresentation of Selected Abstracts
16:45 - 18:15
Critical Review: Colorectal Cancer - Critical Review of Presented Trials and Implication in Practice
Chair: C.J.H. Van de Velde (Netherlands)
Chair: J. Gore-Booth (France)
Medical oncology perspective Speaker: To be announced
Radiation oncology perspective Speaker: D. Sebag-Montefiore (United Kingdom)
Surgical oncology perspective Speaker: C. Coco (Italy)
What is the value of these new treatments? Speaker: C. Marijnen (Netherlands)
Panel Discussion
Medical oncologist Panel: C. Earl (Canada)
Radiation oncologist Panel: D. Sebag-Montefiore (United Kingdom)
Surgical oncologist Panel: C. Coco (Italy)
Pathologist Panel: To be announced
Oncology nurse Panel: To be announced
Patient advocate Panel: J. Gore-Booth (France)
MONDAY 30 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Colon Cancer
Case presentation Moderator: E. Angenete (Sweden)
Surgical oncologist Panel: G. Poston (United Kingdom)
Medical oncologist Panel: C.J.A. Punt (Netherlands)
Radiation oncologist Panel: V. Valentini (Italy)
Imaging specialist Panel: R.G.H. Beets-Tan (Netherlands)
Pathologist Panel: To be announced
Oncology nurse Panel: C. Taylor (United Kingdom)
22 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 23ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
GENERAL SESSIONS GENERAL SESSIONSGYNAECOLOGICAL CANCER
SATURDAY 28 JANUARY 2017
16:45 - 18:15
Clinical Symposium: Gynaecological Cancer - Early Cervical Cancer: Innovative Surgery Versus Innovative Radiotherapy
Chair: To be announced
Chair: To be announced
Image Guided Brachytherapy in Locally Advanced Cervical Cancer: improved pelvic control and survival in RetroEMBRACE, a multi-centred cohort study Speaker: R. Pötter (Austria)
Total mesometrial resection (TMMR) in cervical cancer with therapeutic lymph-adenectomy and avoidance of adjuvant radiotherapy translated to robotic surgery Speaker: P. Wimberger (Germany)
Pivotal Trial: PARP-inhibitor maintenance therapy in patients with BRCA mutation and platinum-sensitive serous ovarian cancer relapse Speaker: To be announced
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial Speaker: M. Gore (United Kingdom)
Discussion
SUNDAY 29 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Gynaecology
Case Presentation:
1: High-risk endometrial cancer 2: Uterus sarcoma after morcellementModerator: P. Wimberger (Germany)
Medical oncologistPanel: M. Gore (United Kingdom)
Radiation oncologistPanel: R. Nout (Netherlands)
Imaging specialistPanel: V. Vandecaveye (Belgium)
PathologistPanel: W.G. McCluggage (United Kingdom)
GynaecologistPanel: H. Nijman (Netherlands)
Oncology nursePanel: To be announced
HAEMATOLOGY
SATURDAY 28 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Lymphoma
Case presentationModerator: F. Cavalli (Switzerland)
HaematologistPanel: M. Ladetto (Italy)
PathologistPanel: To be announced
Radiation oncologistPanel: L. Specht (Denmark)
Nuclear medicine physicianPanel: F. Bodere (France)
Oncology nursePanel: J. De Munter (Belgium)
SUNDAY 29 JANUARY 2017
16:45 - 18:15
Critical Review: Haematology - Critical Review of Presented Trials and Implication in Practice
Chair: E. Kimby (Sweden)
Chair: S. Diler (Turkey)
Chemotherapy free in follicular lymphoma
Speaker: E. Kimby (Sweden)
What’s new in multiple myeloma?
Speaker: To be announced
PET-guided treatment of HL
Speaker: M. Hutchings (Denmark)
Biological determinants in the treatment of CLL
Speaker: D. Rossi (Switzerland)
What is the value of these new treatments? Speaker: To be announced
Panel Discussion
Haematologist Panel: E. Kimby (Sweden)
Haematologist Panel: To be announced
Nuclear medicine physician Panel: M. Hutchings (Denmark)
Haematologist Panel: D. Rossi (Switzerland)
Paediatric oncologist Panel: M. Schrappe (Germany)
Patient Advocate - Myeloma Panel: S. Diler (Turkey)
24 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 25ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
GENERAL SESSIONS GENERAL SESSIONSHEAD AND NECK CANCER
SATURDAY 28 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Head and Neck
Case presentationModerator: V. Gregoire (Belgium)
Surgical oncologistPanel: C.R. Leemans (Netherlands)
Medical oncologistPanel: J. Machiels (Belgium)
Radiation oncologistPanel: H. Langendijk (Netherlands)
Imaging specialistPanel: To be announced
PathologistPanel: K. Hunter (United Kingdom)
Oncology nursePanel: To be announced
10:15 - 11:15
Clinical Symposium: Head and Neck Cancer - Trials and Outcome Research that Change Practice
Chair: L.E. Smeele (Netherlands)
Chair: To be announced
Meta-analysis on the role of induction chemotherapy in locally advanced H&N SCCSpeaker: W. Budach (Germany)
Role of induction chemotherapy in the management of nasopharyngeal carcinomaSpeaker: D. Kwong (China)
Role of immune blocker in metastatic and recurrent HNSCCSpeaker: L.L. Siu (Canada)
Molecular stratification of head and neckSpeaker: M. Baumann (Germany)
15:00 - 16:30
Proffered Papers: Head and Neck CancerPresentation of Selected Abstracts
16:45 - 18:15
Critical Review: Head & Neck Cancer - Critical Review of Presented Trials and Implication in Practice
Chair: C. Grau (Denmark)
Chair: H. Korn (Germany)
Medical oncology perspectiveSpeaker: L. Licitra (Italy)
Radiation oncology perspectiveSpeaker: V. Gregoire (Belgium)
Surgical oncology perspectiveSpeaker: J.L. Lefebvre (France)
What is the value of these new treatments?Speaker: C. Grau (Denmark)
Panel discussion
Medical oncologistPanel: L. Licitra (Italy)
Radiation oncologistPanel: V. Gregoire (Belgium)
Surgical oncologistPanel: J.L. Lefebvre (France)
Oncology nursePanel: M. Wells (United Kingdom)
Patient advocatePanel: H. Korn (Germany)
MELANOMA
SATURDAY 28 JANUARY 2017
10:15 - 11:15
Clinical Symposium: Melanoma - Trials and Outcome Research that Change Practice
Chair: To be announced
Chair: J.B.A.G. Haanen (Netherlands)
Reductor Trial Phase II neoadjuvant anit BRAF, anti MEK treatment in primary inoperable stage III melanomaSpeaker: J.B.A.G. Haanen (Netherlands)
Checkpoint blockade and radiation therapy for brain metastasesSpeaker: To be announced
Title to be announcedSpeaker: To be announced
Ipi adjuvant trial (EORTC 18071) Speaker: A.M.M. Eggermont (France)
SUNDAY 29 JANUARY 2017
15:00 - 16:30
Proffered Papers: MelanomaPresentation of Selected Abstracts
16:45 - 18:15
Critical Review: Melanoma - Critical Review of Presented Trials and Implication in Practice Chair: D. Schadendorf (Germany)
Chair: G. Spurrier-Bernard (France)
Medical oncology perspectiveSpeaker: P.A. Ascierto (Italy)
Surgical oncology perspectiveSpeaker: A. Van Akkooi (Netherlands)
Radiation oncology perspectiveSpeaker: To be announced
What is the value of these new treatments?Speaker: D. Schadendorf (Germany)
Panel discussion
Medical oncologistPanel: P.A. Ascierto (Italy)
Surgical oncologistPanel: A. Van Akkooi (Netherlands)
Radiation oncologistPanel: To be announced
Oncology nursePanel: To be announced
Patient advocacyPanel: G. Spurrier-Bernard (France)
26 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 27ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
GENERAL SESSIONS GENERAL SESSIONSPALLIATIVE AND SUPPORTIVE CARE
SATURDAY 28 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Palliative and Supportive Care - End of Life
Moderator: T. Saarto (Finland)
Case Presentation: Advanced Pancreatic Cancer Speaker: F. Strasser (Switzerland)
Case Presentation: GBM in young person with dependents Speaker: P. Hoskin (United Kingdom)
Case Presentation: Advanced Prostate Cancer Speaker: A. Charalambous (Cyprus)
Radiation oncologistPanel: P. Hoskin (United Kingdom)
Palliative care specialistPanel: T. Saarto (Finland)
Medical oncologistPanel: F. Strasser (Switzerland)
Medical oncologist - painPanel: N.I. Cherny (Israel)
Oncology nursePanel: A. Charalambous (Cyprus)
Oncology nursePanel: H. Ullgren (Sweden)
SUNDAY 29 JANUARY 2017
10:15 - 11:15
Clinical Symposium: Palliative and Supportive Care - Trials and Outcome Research that Change Practice
Chair: P. Hoskin (United Kingdom)
Chair: H. Wildiers (Belgium)
IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastasesSpeaker: P. Hoskin (United Kingdom)
Single-fraction versus 5-fraction radiation therapy for metastatic epidural spinal cord compression in patients with limited survival prognoses: Results of a matched-pair analysisSpeaker: D. Rades (Germany)
Early palliative care for patients with advanced cancer: A cluster-randomised controlled trialSpeaker: C. Zimmermann (Canada)
Discussing prognosis and end-of-life care in the final year of life: A randomised controlled trial of a nurse-led communication support programme for patients and caregiversSpeaker: A. Walczak (Australia)
How to introduce Voicing My CHOiCES (TM), an advance care planning guide for adolescents and young adultsSpeaker: To be announced
Discussion
PALLIATIVE AND SUPPORTIVE CARE
15:00 - 16:30
Proffered Papers: Palliative and Supportive Care Presentation of Selected Abstracts
16:45 - 18:15
Critical Review: Palliative and Supportive Care - Critical Review of Presented Trials and Implication in Practice
Chair: S. Kaasa (Norway)
Chair: N. Philippou (Cyprus)
Palliative careSpeaker: I. Higginson (United Kingdom)
Palliative care specialistSpeaker: M. Bakitas (USA)
Psychological aspectsSpeaker: G. Grande (United Kingdom)
What is the value of these new treatments?Speaker: P. Larkin (Ireland)
Panel Discussion
Palliative carePanel: I. Higginson (United Kingdom)
AnaesthesiologyPanel: M. Bakitas (USA)
Psychological aspectsPanel: G. Grande (United Kingdom)
Patient advocatePanel: N. Philippou (Cyprus)
MONDAY 30 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Palliative and Supportive Care - Elderly
Moderator: H. Wildiers (Belgium)
Case Presentation: Breast CancerSpeaker: H. Wildiers (Belgium)
Case Presentation: Lung CancerSpeaker: A. Luciani (Italy)
Case Presentation: Patient with DementiaSpeaker: M. Hamaker (Netherlands)
Geriatric oncologistPanel: M. Hamaker (Netherlands)
Radiation oncologistPanel: D. Rades (Germany)
Palliative care specialistPanel: T. Saarto (Finland)
Surgical oncologistPanel: M. Reed (United Kingdom)
Clinical oncologistPanel: I. Kunkler (United Kingdom)
Oncology nursePanel: C. Kenis (Belgium)
Palliative carePanel: To be announced
28 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 29ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
GENERAL SESSIONS GENERAL SESSIONSRARE CANCERS
SATURDAY 28 JANUARY 2017
10:15 - 11:15
Clinical Symposium: Neuroendocrine Tumours Chair: K. Oberg (Sweden)
Chair: L. Bodei (Italy)
Targeted therapies - Exemplified by Radiant 4 TrialSpeaker: J. Yao (USA)
Radiation therapy - Exemplified by NETTER1 TrialSpeaker: L. Bodei (Italy)
Chemotherapy - Exemplified by latest study informationSpeaker: M. Pavel (Germany)
AdVince - antiviral therapy TrialSpeaker: K. Oberg (Sweden)
15:00 - 16:30
Proffered Papers: Sarcomas Presentation of Selected Abstracts
16:45 - 18:15
Clinical Symposium: Sarcoma Chair: R. Haas (Netherlands)
Chair: To be announced
Structured contribution of patients in developing new treatment standards in sarcomas: Examples from chordoma and desmoid tumoursSpeaker: To be announced
Guideline development in rare cancer: a combined patient-physician effort in sarcomaSpeaker: P. Hohenberger (Germany)
Why are we still giving doxorubicin in first line metastatic soft tissue sarcoma?Speaker: W. Van der Graaf (United Kingdom)
Specialist teams or specialised networks for rare cancerSpeaker: To be announced
Discussion
SUNDAY 29 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Neuroendocrine Tumours
Case presentation:
1: Pancreatic NETCase presentation
2: Small bowel NETModerator: P. Hellman (Sweden)
Medical oncologistPanel: D. O'Toole (Ireland)
Surgical oncologistPanel: P. Hellman (Sweden)
Radiation oncologistPanel: L. Bodei (Italy)
Imaging specialistPanel: A. Sundin (Sweden)
PathologistPanel: To be announced
Oncology nursePanel: L. Davies (United Kingdom)
THORACIC CANCER
SATURDAY 28 JANUARY 2017
15:00 - 16:30
Proffered Papers: Thoracic Cancer
Presentation of Selected Abstracts
SUNDAY 29 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Thoracic Cancer
Case presentationModerator: J. Jassem (Poland)
Medical oncologistPanel: W. Eberhardt (Germany)
Radiation oncologistPanel: D. De Ruysscher (Netherlands)
PneumologistPanel: E. Smit (Netherlands)
Surgical oncologistPanel: M. Wouters (Netherlands)
RadiologistPanel: H. Kauczor (Germany)
Nuclear Medicine PhysicianPanel: K. Herrmann (Germany)
PathologistPanel: To be announced
Oncology NursePanel: A. Olijve (Netherlands)
10:15 - 11:15
Clinical Symposium: Thoracic Cancer - Trials and Outcome Research that Change Practice
Chair: E. Troost (Germany)
Chair: M. Schuler (Germany)
KEYNOTE-010: Anti-PD-1 anitbody therapy with or without biomarker?Speaker: E. Felip (Spain)
Combined CFRT and SABR in Stage II and III NSCLC with peripheral tumours smaller than 5 cmSpeaker: J.S.A. Belderbos (Netherlands)
Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC): A feasibility studySpeaker: To be announced
New insights in real-world surgical care for lung cancer patientsSpeaker: H. Schreurs (Netherlands)
MONDAY 30 JANUARY 2017
10:15 - 11:45
Critical Review: Thoracic Cancer - Critical Review of Presented Trials and Implication in Practice
Chair: J.C. Soria (France)
Chair: B. Van Herk (Netherlands)
Medical oncology perspectiveSpeaker: M. Schuler (Germany)
Radiation oncology perspectiveSpeaker: D. Zips (Germany)
Surgical oncology perspectiveSpeaker: M. Wouters (Netherlands)
What is the value of these new treatments?Speaker: J.C. Soria (France)
Panel Discussion
Medical oncologistPanel: M. Schuler (Germany)
Radiation oncologistPanel: D. Zips (Germany)
Surgical oncologistPanel: M. Wouters (Netherlands)
Molecular pathologistPanel: L. Conradi (Germany)
Oncology nursePanel: A. Charalambous (Cyprus)
Patient advocatePanel: B. Van Herk (Netherlands)
30 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 31ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
GENERAL SESSIONS GENERAL SESSIONSUPPER GI
SUNDAY 29 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Upper GI - Hepatobillary
Case presentation: High risk liver metastasesModerator: G. Poston (United Kingdom)
Surgical oncologistPanel: C. Verhoef (Netherlands)
Medical oncologistPanel: G. Folprecht (Germany)
Radiation oncologistPanel: R. Sharma (United Kingdom)
RadiologistPanel: To be announced
PathologistPanel: L. Rubbia-Brandt (Switzerland)
Oncology nursePanel: To be announced
10:15 - 11:15
Clinical Symposium: Upper GI Cancer - Trials and Outcome Research that Change Practice Chair: M. Verheij (Netherlands)
Chair: G. Folprecht (Germany)
Management of gastric cancer with low volume metastatic disease (REGATTA trial)Speaker: H.H. Hartgrink (Netherlands)
HPB: Liver limited colorectal metastases (CLOCC and SIRFLOX/FOXFIRE)Speaker: To be announced
CRITICS trial plus ASCO 2016Speaker: E. Jansen (Netherlands)
Long term results of CLOCC trialSpeaker: T.J.M. Ruers (Netherlands)
MONDAY 30 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Upper GI - Oesophageal Cancer
Case presentation: Non-responders to neoadjuvant therapyModerator: W. Allum (United Kingdom)
Surgical oncologistPanel: B.P.L. Wijnhoven (Netherlands)
Medical oncologistPanel: To be announced
Radiation oncologistPanel: K. Haustermans (Belgium)
PathologistPanel: H. Grabsch (Netherlands)
DietitianPanel: C. Shaw (United Kingdom)
09:00 - 10:15
Proffered Papers: Upper GI
Presentation of Selected Abstracts
10:30 - 11:45
Critical Review: Upper GI Cancer - Critical Review of Presented Trials and Implication in Practice
Chair: To be announced
Chair: To be announced
Medical oncology perspectiveSpeaker: To be announced
Radiation oncology perspectiveSpeaker: To be announced
Surgical oncology perspectiveSpeaker: D. D'Ugo (Italy)
What is the value of these new treatments?Speaker: To be announced
Panel Discussion
Medical oncologistPanel: To be announced
Radiation oncologistPanel: To be announced
Surgical oncologistPanel: D. D'Ugo (Italy)
Patient advocacyPanel: To be announced
Oncology nursingPanel: J. Rundgren (Sweden)
UROLOGY
SATURDAY 28 JANUARY 2017
15:00 - 16:30
Proffered Papers: Urology Presentation of Selected Abstracts
SUNDAY 29 JANUARY 2017
07:45 - 08:45
Multidisciplinary Tumour Board: Urology
Case presentationModerator: T. De Reijke (Netherlands)
Medical oncologistPanel: A. Templeton (Switzerland)
Imaging specialistPanel: H.P. Schlemmer (Germany)
PathologistPanel: E. Comperat (France)
Surgical oncologistPanel: S. Joniau (Belgium)
Radiation oncologistPanel: B. Jereczek-Fossa (Italy)
Oncology nursePanel: E. Van Muilekom (Netherlands)
10:15 - 11:15
Clinical Symposium: Urology - Bladder Cancer
Chair: H. Van Poppel (Belgium)
Chair: B. Jereczek-Fossa (Italy)
Standard or extended pelvic lymphadenectomy in treating patients undergoing surgery for invasive bladder cancerSpeaker: S.P. Lerner (USA)
Immediate surgery or surgery after Sunitinib Malate in treating patients with metastatic kidney cancerSpeaker: A. Bex (Netherlands)
Impact of radical prostatectomy as primary treatment in patients with prostate cancer with limited bone metastasesSpeaker: To be announced
Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renalcel carcinomaSpeaker: L. Albiges (France)
MONDAY 30 JANUARY 2017
10:15 - 11:45
Critical Review: Urology - Critical Review of Presented Trials and Implication in Practice
Chair: C.N. Sternberg (Italy)
Chair: M. Kirby (United Kingdom)
Urology perspectiveSpeaker: N. Mottet (France)
Medical oncology perspectiveSpeaker: L. Albiges (France)
Radiation oncology perspectiveSpeaker: K. Haustermans (Belgium)
What is the value of these new treatments?Speaker: C.N. Sternberg (Italy)
Panel discussion
UrologistPanel: N. Mottet (France)
Medical oncologistPanel: L. Albiges (France)
Radiation oncologistPanel: K. Haustermans (Belgium)
Oncology nursePanel: E. Van Muilekom (Netherlands)
General PractitionerPanel: M. Kirby (United Kingdom)
Patient AdvocatePanel: K. Mastris (Belgium)
32 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 33ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
GENERAL SESSIONSOUTCOME RESEARCH
SATURDAY 28 JANUARY 2017
13:15 - 14:45
Changing Practice Session: Yes, Data Can Talk Together
Chair: J. Bogaerts (Belgium)
Chair: P. Selby (United Kingdom)
United Kingdom: Public health England, National cancer Intelligence Network (NCIN)Speaker: C. Carrigan (United Kingdom)
EU: Rare Cancer (rarecare Net), high resolution data to support implementation studies: A pilot on head and neck cancerSpeaker: A. Trama (Italy)
Belgium: Quality indicator studies led by KCESpeaker: To be announced
Molecular epidemiology, IARCSpeaker: To be announced
Discussion
SUNDAY 29 JANUARY 2017
11:30 - 12:45
Changing Practice Session: The Value of Cancer Registries Chair: V. Lemmens (Netherlands)
Chair: A. Katalinic (Germany)
Belgium: Innovative methodology to optimise translation of trial outcome to real-world patientsSpeaker: L. Liu (Belgium)
Germany: Population-based quality of life data collection and its impact on daily practiceSpeaker: A. Waldmann (Germany)
Netherlands: The NABON Breast Cancer AuditSpeaker: T. Van Dalen (Netherlands)
United Kingdom: Map the route of cancer diagnosisSpeaker: To be announced
Discussion
MONDAY 30 JANUARY 2017
10:15 - 11:15
Changing Practice Session: External Validity of Clinical Trials
Chair: L. Liu (Belgium)
Chair: B. Flamion (Belgium)
Modelling effectiveness from clinical trialsSpeaker: M. Egger (Switzerland) Incorporating real-life data into drug development: towards more pragmatic trialsSpeaker: M. Mauer (Belgium)
Panel Discussion Panel: M. Egger (Switzerland) Panel: M. Mauer (Belgium) Panel: To be announced Panel: To be announced Panel: F. Pignatti (United Kingdom) Panel: O. Visser (Netherlands)
HEALTH ECONOMICS IN CANCER CARE
SATURDAY 28 JANUARY 2017
11:30 - 12:45
Changing Practice Session: Affordability of Innovation in Cancer Care: How to Bend the Cost Curve in an Era of Technology Evolution Chair: Y. Lievens (Belgium)
Chair: R. Sullivan (United Kingdom)
Global perspective: Prospects of a multidisciplinary approach to oncology careSpeaker: R. Sullivan (United Kingdom)
Balance between accuracy, outcome and cost in innovative radiotherapySpeaker: Y. Lievens (Belgium)
Challenges and opportunities of personalised therapySpeaker: M. Ijzerman (Netherlands)
The cost of innovation: The regulatory perspectiveSpeaker: To be announced
Minister of Health - The NetherlandsSpeaker: To be announced
SUNDAY 29 JANUARY 2017
11:30 - 13:00
Changing Practice Session: Reimbursement and Market Access to Innovative Oncology Treatments
Chair: M. Ijzerman (Netherlands)
Chair: To be announced
Differences in pricing of novel cancer drugs across EuropeSpeaker: W.H. Van Harten (Netherlands)
Reimbursement versus costs of radiotherapy across Europe: Does it impact access?Speaker: J. Borras (Spain)
Innovative approaches to the reimbursement of innovative treatment modalitiesSpeaker: To be announced
Process of cancer care adoption: Beyond the costsSpeaker: To be announced
Minister of Health - ItalySpeaker: To be announced
Discussion
13:15 - 14:30
Changing Practice Session: Value in Oncology Care Chair: To be announced
Chair: B. Jönsson (Sweden)
Surrogate end-points in oncology: The right way to go?Speaker: To be announced
A global approach to outcome: The magnitude of clinical benefit scaleSpeaker: To be announced
Oncology costs in EuropeSpeaker: To be announced
Value for money in oncology: How to combine information of outcome and cost in a multidisciplinary and multinational environmentSpeaker: B. Jönsson (Sweden)
Discussion
MONDAY 30 JANUARY 2017
09:00 - 10:00
Changing Practice Session: Equity in Cancer Care: Still a Long Way to Go
Chair: C. Grau (Denmark)
Chair: To be announced
Differences in access to high quality cancer care across EuropeSpeaker: To be announced
From availability to actual and future needs: The example of radiation oncologySpeaker: C. Grau (Denmark)
Essential requirements for quality cancer care: oncopolicy perspectiveSpeaker: A. Costa (Switzerland)
Dealing with the increasing oncology needs across Europe: Cancer care programs as a means to frame challenges in multidisciplinary oncologySpeaker: To be announced
Discussion
34 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 35ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
ORGANISATION OF CANCER CARE DELIVERY
SUNDAY 29 JANUARY 2017
11:30 - 12:45
Changing Practice Session: Not Every Cancer Centre Should Treat Every Cancer Patient. What's the Evidence?
Chair: M. Wouters (Netherlands)
Quality and/or quantity? Evidence to support centralised complex cancer careSpeaker: J. Borras (Spain)
Cancer centre accreditation: Ensuring equity and qualitySpeaker: S. Oberst (United Kingdom)
How to provide seamless care of the large cancer centres and oncology community practice: The German CML Alliance as a best practice exampleSpeaker: J. Geissler (Germany)
Panel Discussion
11:30 - 12:45
Changing Practice Session: Use of Electronic Tools and Telemedicine in Oncology: "The Doctor Will Skype You Now"
Chair: To be announced
Chair: To be announced
Enhancing cancer patient follow-up care and monitoring using telemedicineSpeaker: To be announced
Patient reported toxicity - Using electronic toolsSpeaker: To be announced
Patient information portals - An innovative approach for involving patients in their own care and reducing the burden on clinical teamsSpeaker: To be announced
Panel discussion on risks and benefits of electronic cancer care delivery
MONDAY 30 JANUARY 2017
09:00 - 10:00
Changing Practice Session: Lung Cancer Screening: Can We Afford Not to? Chair: To be announced
NLST - Design and survival outcomesSpeaker: To be announced
NELSON Trial - Design and survival outcomesSpeaker: To be announced
System readiness, cost effectiveness for lung cancer screening - A Canadian exampleSpeaker: H. Bryant (Canada)
Panel Discussion
REGULATORY
SATURDAY 28 JANUARY 2017
11:30 - 12:45
Regulatory Session: EMA and HTAs On the Hot Seat
Chair: To be announced From drug approval to access – evidentiary standards, can we fill the gap? Speaker: To be announced
Panoramic view of cancer drug HTA in Europe, present and futureSpeaker: J. Mestre-Ferrandis (United Kingdom)
Case study: Kadcyla in HER2+ breast cancerSpeaker: To be announced
Panel Discussion
Panel: To be announced
16:10 - 17:10
Regulatory Session: Case Studies in Approvals of Targeted Agents: Single-Arm Trials Chair: To be announced
Crizotinib in ALK + NSCLC: Development, EU approval and beyondSpeaker: M. Rothenberg (USA)
Single phase 2 trial design for a subset groupSpeaker: To be announced
Regulatory challenges, opportunities and lessons for the futureSpeaker: To be announced
Panel Discussion Panel: To be announced
17:15 - 18:15
Regulatory Session: Real-life Implementation of Biomarker Information to Inform Treatment and Regulatory Decisions - the PD-L1 Experience
Chair: J. Bergh (Sweden)
Challenges with predictive biomarkers for immunotherapiesSpeaker: To be announced
Implementation of biomarker-driven patient selection into routine pathological diagnosticsSpeaker: W. Weichert (Germany)
Harmonising companion diagnostics: Regulatory experienceSpeaker: To be announced
Panel Discussion Panel: To be announced
SUNDAY 29 JANUARY 2017
07:45 - 08:45
Regulatory Session: Patient Involvement in Regulatory Discussions
Chair: J. Geissler (Germany)
The role of patients in the design and support of academic trials for rare cancersSpeaker: To be announced
FDA Patient Advisory GroupSpeaker: To be announced
Patient preference elicitation to design trials and interpret results: Experience with melanoma patientsSpeaker: To be announced
Panel Discussion Panel: To be announced
MONDAY 30 JANUARY 2017
09:00 - 11:00
Regulatory Session: Regulating Innovation in Local Regional Treatment
Details to be announced in the online searchable programme as soon as possible
36 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 37ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
GENERAL SESSIONSPRIMARY CARE PROGRAMME
SATURDAY 28 JANUARY 2017
10:15 - 11:15
Primary Care Session: The Expanding Role of Primary Care in Cancer Management
Chair: D. Weller (United Kingdom)
The vital role of primary care at all stages of the cancer journeySpeaker: D. Weller (United Kingdom)
Facilitated DiscussionFacilitator: I. Banks (Belgium)
11:30 - 12:45
Primary Care Session: Diagnosing Cancer Early - The Most Effective Strategy to Improve Survival: Current Issues in Screening and Diagnosis
Chair: G. Rubin (United Kingdom)
Introduction by the ChairSpeaker: G. Rubin (United Kingdom)
Reducing diagnostic delaySpeaker: R. Neal (United Kingdom)
Designing better pathways to diagnosing cancer / using guidelines to improve cancer diagnosis and referralSpeaker: To be announced
DiscussionModerator: G. Rubin (United Kingdom)
15:00 - 16:30
Primary Care Session: Optimising Treatment and Management of Cancer Patients and Survivors: The Need for Joined-Up Approaches
Chair: T. Saarto (Finland)
Management of cancer patients in primary care
Speaker: To be announced
Multi-morbidity and cancer
Speaker: To be announced
Palliative care and end of life
Speaker: S. Murray (United Kingdom)
Discussion
16:45 - 18:15
Primary Care Session: Integrated Models of Cancer Management: Bringing Primary Care and Secondary Care Together
Introduction by the Chair Chair: To be announced
Integrated models of cancer management
Speaker: E. Grunfeld (Canada)
Panel Discussion
Panel: B. Zirbs Savigny (Switzerland)
Panel: To be announced
Panel: D. Cameron (United Kingdom)
Panel: J. Wilkinson (Belgium)
Panel: To be announced
Panel: I. Banks (Belgium)
PATIENT ADVOCACY
SUNDAY 29 JANUARY 2017
10:15 - 11:15
Patient Advocacy Session - Side Effects: Out of Sight Out of Mind
Details to be announced in the online searchable programme as soon as possible
15:00 - 16:30
Patient Advocacy Session: Translating Research into Patient Value
Chair: G. Spurrier-Bernard (France)
Chair: J. Geissler (Germany)
What patients want to know about researchSpeaker: To be announcedPatient centric research design - from theory to practice Speaker: To be announced
Panel Discussion: Is randomisation still ethical?Moderator: B. Ryll (Sweden)Panel: A.M.M. Eggermont (France)
16:45 - 18:15
Patient Advocacy Session: Controversies in Care - Myths and Realities Chair: K. Oliver (United Kingdom)
Chair: W. Tse Yared (Belgium)
Are informed patients and caregivers a threat? - video vignettes and discussionModerator: J. Pelouchova (Czech Republic)
Lost in transition: smoothing the way from paediatric to adult cancer careSpeaker: To be announced
Panel discussion: Coping for caregivers: supporting a loved one's journey through palliative care and end of lifeModerator: To be announcedPanel: K. Oliver (United Kingdom)Panel: J. Pelouchova (Czech Republic)Panel: To be announced
PICTURE
38 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 39ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
ONCOPOLICY
SATURDAY 28 JANUARY 2017
13:15 - 14:45
Policy Session I: How can Oncopolicy Strengthen Multidisciplinary Practice?
Details to be announced in the online searchable programme as soon as possible
SUNDAY 29 JANUARY 2017
13:15 - 14:45
Policy Session II: Meeting the Challenges of Cross-Border Cancer Care
Details to be announced in the online searchable programme as soon as possible
EDUCATIONAL
FRIDAY 27 JANUARY 2017
08:00 - 12:00
Educational Session: Leadership Programme - Part IModerator: D. Ashton (United Kingdom)
14:30 - 17:00
Educational Session: Leadership Programme - Part IIModerator: D. Ashton (United Kingdom)
SATURDAY 28 JANUARY 2017
07:45 - 08:45
Educational Session: How to Efficiently Run a Tumour Board
Chair: G. Poston (United Kingdom)
Speaker: H. Malik (United Kingdom)
Speaker: L. Lundvall (Denmark)
Speaker: To be announced
Discussion
10:15 - 11:45
Educational Immersion Programme: Introduction to Omics and Personalised Medicine (Novice)
Chair: I.F. Tannock (Canada)
Principles of molecular characterisation of tumoursSpeaker: R. Bernards (Netherlands)
How drugs might target tumour mutationsSpeaker: J. Rodon (Spain)
Clinical trials evaluating personalised medicineSpeaker: C. Le Tourneau (France)
Problems that limit personalised medicineSpeaker: I.F. Tannock (Canada)
Discussion
10:15 - 11:45
Educational Session: Can we Afford it? How to Determine Cost Effectiveness
Chair: F. Pignatti (United Kingdom)
How to evaluate cost-effectivenessSpeaker: B. Jönsson (Sweden)
Cost-effectiveness in evaluating new technologySpeaker: C. Uyl de Groot (Netherlands)
Role of cost effectiveness in defining cancer policySpeaker: T. Albreht (Slovenia)
Panel discussion
10:15 - 12:15
Educational Session: Research Opportunities: How to Reach the Stars and Improve Your Career Chair: P. Bonomo (Italy)
Chair: D. Fontein (Switzerland)
Surgical oncology perspectiveSpeaker: S. Evrard (France)
Radiation oncology perspectiveSpeaker: D. Zips (Germany)
Medical oncology perspectiveSpeaker: M. Schuler (Germany)
Translational clinician-scientist perspectiveSpeaker: To be announced
Industry perspectiveSpeaker: S. Galbraith (United Kingdom)
Discussion
11:30 - 13:00
Educational Session: Real World Data: Health Outcomes Research
Chair: J.G. Eriksen (Denmark)
How to explore large databases and correct for biasSpeaker: C. Booth (Canada)
Lessons to be learned from large databasesSpeaker: V. Lemmens (Netherlands)
Extrapolation from trials to real lifeSpeaker: A. Templeton (Switzerland)
Discussion
40 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 41ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
EDUCATIONAL
11:30 - 13:00
Educational Session: Cancer Imaging: A Key Component of Personalised Oncology
Chair: E.G.E. De Vries (Netherlands)
Appropriate use of FDG-PET in the daily management of solid cancersSpeaker: W.J.G. Oyen (United Kingdom)
Whole body MRI: A shifting paradigm for metastatic bone diseaseSpeaker: A.R. Padhani (United Kingdom)
Using imaging as a tools for improved anti-cancer drug tailoring in prospective clinical trialsSpeaker: G. Gebhart (Belgium)
Discussion
11:30 - 13:00
Educational Session: Recognising and Managing Ethical Challenges in Cancer Care
Chair: To be announced
Ethical behaviour on the oncology team
Speaker: To be announced
Ethics of selecting and stopping cancer treatment
Speaker: To be announced
Ethical interactions with Pharma
Speaker: E.A. Eisenhauer (Canada)
Panel discussion
Panel: To be announced
Panel: To be announced
Panel: E.A. Eisenhauer (Canada)
Panel: B. Van Herk (Netherlands)
15:00 - 17:00
Educational Session: Collaboration in Oncology
Chair: M. Hutka (United Kingdom)
Chair: B. Sousa (Portugal)
Leading others and the art of negotiationSpeaker: To be announced
Conflict resolution and optimising team performanceSpeaker: To be announced
Workshop Panel: To be announced Panel: C. Taylor (United Kingdom)
15:45 - 18:15
Educational Immersion Programme: Personalised Medicine: From Genomics to Clinical Practice (Advanced) Chair: M. Piccart (Belgium)
Molecular pathologistSpeaker: J.S. Reis-Filho (USA)
Interpreting NGS dataSpeaker: A. Irrthum (Belgium)
Intra-tumour heterogeneity and limits to personalised medicineSpeaker: M. Gerlinger (United Kingdom)
Prospective clinical trials focusing on molecular imaging as a tool for personalised therapySpeaker: A. Van der Veldt (Netherlands)
Implementation of personalised medicine in daily practice: RadiotherapySpeaker: P. Lambin (Netherlands)
Implementation of personalised medicine in daily practice: Medical oncology Speaker: P.G. Aftimos (Belgium)
Implementation of personalised medicine in daily practice: SurgerySpeaker: K. Soreide (Norway)
Clinical trials of personalised medicine: A critical look to the future
Speaker: F. André (France) Discussion
16:15 - 18:15
Educational Session: Evidence-based Management of Cancer in Older Patients
Chair: R.A. Audisio (United Kingdom)
Practical geriatric assessment in older cancer patients
Speaker: C. Kenis (Belgium)
Tailoring cancer surgery to older patients
Speaker: R.A. Audisio (United Kingdom)
Adapting radiotherapy to older patients
Speaker: I. Kunkler (United Kingdom)
Adapting systemic therapy for older patients
Speaker: S. Monfardini (Italy)
Tumour Board: Two cases
EDUCATIONAL
16:45 - 18:15
Educational Session: Tomorrow's Clinical/Practical Applications of Liquid Biopsy
Chair: M. Ignatiadis (Belgium)
Overview of circulating tumour cellsSpeaker: C. Dive (United Kingdom)
Circulating tumour cells: Challenges and opportunities on the path to clinical utilitySpeaker: M. Ignatiadis (Belgium)
Circulating tumour DNA: TodaySpeaker: L. De Mattos-Arruda (Spain)
Potential of microRNAs and new circulating biomarkersSpeaker: G. Sozzi (Italy)
Discussion
SUNDAY 29 JANUARY 2017
07:45 - 08:45
Educational Session: How to Efficiently Run a Tumour Board (Repeated)
For details please refer to sessions scheduled on Saturday
10:15 - 11:45
Educational Session: Can we Afford it? How to Determine Cost Effectiveness (Repeated)For details please refer to sessions scheduled on Saturday
10:15 - 12:15
Educational Session: Acquiring Practical Skills: Designing projects, Effectiveness in Writing, Funding Your Research and Speaking Chair: L. De Mattos-Arruda (Spain)
How to do a systematic review: The first task of any studySpeaker: To be announced
How to design an academic trial and get it funded by PharmaSpeaker: To be announced
Role of foundations in funding academic researchSpeaker: F. Cardoso (Portugal)
How to present your research effectively - In a paper, talk or posterSpeaker: I.F. Tannock (Canada)
Discussion
11:15 - 12:45
Educational Immersion Programme: Introduction to Immunotherapy and the Science Behind it (Novice)
Chair: G. Curigliano (Italy)
Fundamentals of tumour immunologySpeaker: I.M. Svane (Denmark)
Approaches to immunotherapy - What works, what doesn't?Speaker: To be announced
Clinical experience with immunotherapy: How to man-age the side-effectsSpeaker: C. Blank (Netherlands)
Discussion
11:30 - 13:00
Educational Track
Educational Session: Patient Reported Outcomes
Chair: F.A. Peccatori (Italy)
Are PROs ready to be accepted as primary endpoints of clinical trials?
Speaker: To be announced
The NCI PRO-CTCAE project
Speaker: To be announced
Revisiting ovarian cancer trials using PROs
Speaker: M. Friedlander (Australia)
Panel Discussion
Panel: To be announced
Panel: To be announced
Panel: M. Friedlander (Australia)
Patient advocate
Panel: S. Erdem (Turkey)
42 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 43ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
EDUCATIONAL
15:00 - 17:30
Educational Immersion Programme: Advanced Course in Immunology and Immunotherapy (Advanced)
Chair: To be announced
The emerging science of tumour immunologySpeaker: L. Zitvogel (France)
Checkpoint inhibitors and biomarkers in clinical practice: Predicting respondersSpeaker: P.A. Ascierto (Italy)
Integration of radiotherapy and chemotherapy in immuno-based treatmentSpeaker: K. Harrington (United Kingdom)
How can we afford these new immunotherapy drugs?Speaker: To be announced
Critical perspective on the future of immunotherapySpeaker: J.B.A.G. Haanen (Netherlands)
Discussion
15:00 - 16:30
Educational Session: Improving Patient Safety in Oncology Chair: R. Canetta (USA) Disclosing and reporting medical errors
Speaker: To be announced
Evidence-based methods to improve safety of cancer surgery
Speaker: To be announced
Patient centred attention to safety
Speaker: A. Kullberg (Sweden)
Discussion
15:00 - 16:30
Educational Session: Real World Data: Health Outcomes Research (Repeated)
For details please refer to sessions scheduled on Saturday
MONDAY 30 JANUARY 2017
08:30 - 10:00
Educational Session: Recognising and Avoiding Bias in Clinical Trials
Chair: E.A. Eisenhauer (Canada)
Patient selection, wrong endpoints and biases that limit application of clinical trials
Speaker: E. Meershoek-Klein Kranenbarg (Netherlands)
Spin in the reporting of clinical trials
Speaker: To be announced
Under-reporting of harm
Speaker: B. Seruga (Canada)
Lies, damned lies and statistics
Speaker: To be announced
Discussion
09:00 - 10:30
Educational Session: Inefficiencies in Cancer Care
Chair: To be announced
Inefficiencies in cancer care
Speaker: To be announced
Where to save costs without loss of effectiveness
Speaker: To be announced
Efficient use of radiotherapy - Do we always need high-tech and multiple fractions?
Speaker: J. Grau Eriksen (Denmark)
Panel Discussion
Panel: To be announced
Panel: To be announced
Panel: J. Grau Eriksen (Denmark)
Panel: B. Jönsson (Sweden)
EDUCATIONAL
09:00 - 10:30
Educational Session: Practicing Oncology in Countries with Limited Resources
Chair: F. Cavalli (Switzerland)
Matching surgical treatment of cancer with patient expectations
Speaker: Z. Mátrai (Hungary)
Applying ESMO or ASCO guidelines for "value" in selecting cancer treatment
Speaker: To be announced
Optimising the role of the oncology nurse
Speaker: K. Lokar (Slovenia)
Discussion
10:15 - 11:45
Educational Session: Evidence-Based Public Health Interventions to Prevent Cancer
Chair: P. Autier (France)
An ethicist's view of screening policiesSpeaker: To be announced
Benefits, uncertainties and costs associated with screening for colorectal cancerSpeaker: I. Lansdorp-Vogelaar (Netherlands)
Effectiveness and cost-effectiveness of HPV vaccinationSpeaker: To be announced
Discussion
44 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
KEY DATES
SUBMIT YOUR ABSTRACT!
LATE-BREAKING ABSTRACTS
Showcase your latest scientific data at ECCO2017 – European Cancer Congress, the multidisciplinary meeting for all cancer types, addressing all oncology disciplines and related healthcare professions.
ECCO2017 will have a direct impact on clinical practice and will gather thousands of oncologists from Europe and around the world. This is your chance to present your data before Europe’s unique multidisciplinary oncology platform.
We are looking for novel and practice-changing phase III trial data as well as real-world outcome data. Reaching a global audience, ECCO2017 has an extensive media programme for scientific media worldwide. Submitting your practice changing data for presentation at ECCO2017 will ensure its global visibility.
Late-breaking abstracts describe the latest advances that will change our daily clinical practice.
Focus is placed on capturing abstracts with ground-breaking and unique data that would have been presented for the first time.
Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial; a Phase II study showing anti-tumour activity in a novel context.
25 APRIL 2016 Abstract Submission Opens
25 AUGUST 2016 Abstract Submission Deadline
23 NOVEMBER 2016 Late-Breaking Abstract Submission Opens
7 DECEMBER 2016 Late-Breaking Abstract Submission Deadline
For the full Call for Abstracts, visit: eccocongress.org/abstracts
Breast Cancer
Multi-ModalityRadiotherapySurgerySystemic Therapy
Rare Cancers: Sarcoma
Multi-ModalityRadiotherapySurgerySystemic Therapy
Central Nervous System
Multi-ModalityRadiotherapySurgerySystemic Therapy
Rare Cancers: NET
Multi-ModalityRadiotherapySurgerySystemic Therapy
Gastrointestinal Malignancies - Colorectal Cancer
Multi-ModalityRadiotherapySurgerySystemic Therapy
Supportive Care and Palliation
Palliative CarePsychosocial AspectsQuality of LifeSupportive Care
Gastrointestinal Malignancies - Upper GI
Multi-ModalityRadiotherapySurgerySystemic Therapy
Outcome ResearchClinical Outcomes Studies Real World DataPatient-Reported Outcomes
Urology
Multi-ModalityRadiotherapySurgerySystemic Therapy
Health Economics of Cancer Cost Studies
Gynaecological Cancer
Multi-ModalityRadiotherapySurgerySystemic Therapy
Health PolicyHealth Care Use & Policy Studies
Haematological MalignanciesRadiotherapySystemic TherapyRadiology
Organisation of Cancer Care Delivery
Head and Neck Cancer
Multi-ModalityRadiotherapySurgerySystemic Therapy
Survivorship
Thoracic Oncology
Multi-ModalityRadiotherapySurgerySystemic Therapy
Screening and prevention
Melanoma
Multi-ModalityRadiotherapySurgerySystemic Therapy
Community Cancer Care
Paediatric Oncology Childhood Cancer
Multi-ModalityRadiotherapySurgerySystemic Therapy
Other
Topic TopicSubtopic Subtopic
ABSTRACT TOPIC CATEGORIES
45
CALL FOR ABSTRACTSCALL FOR ABSTRACTS
46 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 47ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 47
Through the generosity of the ECCO2017 European Cancer Congress Sponsors,
• 20 Fellowship Grants are offered to young oncology professionals from countries with lower-middle income economies as per World Bank classification to attend the congress
• 20 Fellowship Grants are offered to young oncology professionals from Eastern European countries
To meet the requirements to be considered for a fellowship grant the applicant should:
• Submit an abstract for the ECCO2017 European Cancer Congress. Applicants whose abstracts have been accepted for an oral or poster presentation at the congress will be considered first.
• Submit the online Fellowship Grant application form ONLY ONCE irrespective of the number of abstracts submitted by the applicant.
• Be under the age of 40.
• Provide a letter of support from the Head of the Department/Organisation stating that the applicant is not the recipient of any other financial support.
• Provide a two page CV (including date of birth).
• Be fluent in English.
The deadline for receipt of applications is 25 August 2016. Incomplete applications will not be considered.
Each fellowship will include:
• Free registration to the congress
• Free accommodation in one of the selected hotels (maximum 3 nights)
• 500 EUR travel grant – to meet the travel expenses from Eastern European Countries
• Reimbursement of travel costs up to 1200 EUR based on an apex return airfare in economy class from countries with lower-middle income economies
• Reimbursement after the congress
FELLOWSHIP GRANTSAPPLICATION
FELLOWSHIP GRANTSAPPLICATION THE DEADLINE FOR RECEIPT OF APPLICATIONS IS 25 AUGUST 2016.
TO APPLY PLEASE COMPLETE THE ONLINE APPLICATION FORM.If you have NOT yet submitted an abstract for the congress go to: www.eccocongress.org
Please note that the Abstract Submission is open until 25 August 2016.
Fellowship applications can only be submitted online. Applications submitted by post, fax or email will not be considered.
Successful applicants will be notified by early November 2016.
On the first day of the Congress (January 27th, 2017), SIOPE will present a highly innovative programme for its community of professionals working in the field of childhood cancers.
Cancer is the biggest threat to children’s lives after safety incidents, and here at this Congress experts from paediatric cancer groups and national societies will share their crucial research results to tackle this major problem.
This SIOPE Society Day will focus on the most demanded and needed educational topics in paediatric oncology. Covering both the latest innovations and the lessons learnt, and building on the existing cooperation with the adult oncology world, this educational session will be extremely informative and useful to illustrate the most effective approaches at the clinical and research levels.
The second part of the Society Day will consist in a SIOPE Policy Session, focusing in particular on possible funding opportunities for the implementation of the SIOPE Strategic Plan ‘A European Cancer Plan for Children and Adolescents’, where the importance of exchange on EU health and research policies and future initiatives of the SIOPE community will be emphasised.
Experiences from multidisciplinary tumour boards in Europe, as well as clinical symposia on the most frequent types of childhood cancers (leukaemia, CNS and brain tumours, sarcomas), on translational approaches and on immunotherapy will also make part of the overall Programme of ECCO2017, making it a not-to-be-missed appointment for all professionals willing to ensure the best possible outcome to children and adolescents with cancer.
The European Cancer Congress ECCO2017 is THE event for all oncological professionals in Europe, with exclusive multidisciplinary sessions illustrating important discoveries from state-of-the-art cancer research studies.
SIOPE Society DayJanuary 27th, 2017
Credits: Attilio Rossetti for SIOPE - the European Society for Paediatric Oncology
48 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 49ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
THE ESTRO WORKSHOPSAT ECCO2017
Radiation Oncology is one of the main pillars of oncology care. According to evidence-based recommendations, across Europe, around half of all patients diagnosed with cancer would benefit from radiation therapy at some point during the course of their disease. It has however been estimated that in most European countries radiation treatment is provided to only about 60–80% of all patients who should receive it.
The ESTRO symposium focuses on the factors and determinants that impact access, efficiency and quality of radiotherapy, giving an insight on the ESTRO perspective and vision.
Topics discussed by the panellists will include:
Access:• the availability, needs
and sustainability of radiotherapy resources; now and in the future
• safeguarding innovation in radiotherapy, accounting for socio-economic variables
• the organisation of radiotherapy services in the context of cancer control programs in order to improve accessibility
Efficiency:• optimising processes in
radiotherapy
• seeking the optimal balance between outcomes and costs
Quality:• safety through quality
assurance programs in Radiation Oncology
• radiotherapy contribution to the multidisciplinary cancer care approach
• the importance of interaction between doctors and other stakeholders
Aims1. Introduce basic
communication concepts and competence to the European cancer community
2. Help participants to deal efficiently with difficult communication tasks in a way that make them – and the patients – feel better afterwards
Methods• Blend of interactive
lectures, activities in groups of 2–20 and plenary take-homes
• Highly learner-centered, scheduled program adjusted to participants’ needs as we teach
Program themes• Basics of efficient
communication
• Disclosing uncertainty – breaking bad news
• Delivering complex information
• Shared decision-making and follow-up
The workshop comprises four 90-minute modules.
AudienceRadiation Oncologists, Medical Oncologists, Clinical Oncologists, Surgical oncologists, GP’s, nurses, patient organisations and decision makers.
About the lead facilitatorPål Gulbrandsen is a specialist in public health, former general practitioner and editor, and professor of health services research at the University of Oslo.
TOWARDS STATE-OF-THE-ART RADIOTHERAPY FOR EVERY CANCER PATIENT: WHAT IS AT STAKE?
COMMUNICATION IN ONCOLOGY
Oncopolicy Workshop:January 27, 2017
Communication Workshop: January 27, 2017
Chairs:Yolande Lievens, Ghent University Hospital, Belgium Josep M. Borras, University of Barcelona, Spain
Lead facilitator: Pål Gulbrandsen
Co-facilitators: Søren Cold, Clinical Oncologist, PhD and associate professor, University of Southern Denmark. Robert Glynne-Jones, Clinical Oncologist, Mount Vernon Cancer Centre, UK
Three (3) young clinical oncologists can profit from the opportunity to present their novel clinical trial concepts and benefit from expert advice in ‘The Art of Designing Clinical Trials: The Latest in Methods in Clinical Cancer Research’ Workshop scheduled on 30 January 2017.
YOUNG TRIALIST GRANT
SUBMISSION CRITERIA
Candidates must be within 5 years of completion of Residency/Fellowship training in one of the following disciplines:
• Junior physician specialising in oncology;
• Junior clinical professional managing cancer patients (i.e. urologist, gynaecologist, neuro-oncologist, haematologist);
• Junior radiologist or pathologist with a strong involvement in cancer care.
Submit a cancer clinical trial concept which has not been previously written or performed.
• Free registration to the congress
• Opportunity to present in a congress session
• Meet and interact with renowned oncology experts
EACH GRANT WILL INCLUDE:
CLINICAL TRIAL CONCEPT
SUBMISSION DEADLINE: 1 SEPTEMBER 2016
APPLICANTS WILL BE NOTIFIED BY EMAIL REGARDING THE
STATUS OF THEIR APPLICATION IN EARLY OCTOBER 2016.
50 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 51ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
ESSO37-Advert-210x297.indd 1 15/04/16 09:49
As the regulatory and scientific landscapes evolve, we have entered an era of clinical research transformation. From the integration of translational research and biomarker development to clinically relevant end-points and value based treatments in real life, new challenges have emerged. This is not without impact on the methodology of clinical
Future of cancer clinical research and therapy
research and new forms and methods of clinical studies have emerged. Solution-driven innovation is needed while setting up new quality and multidisciplinary standards. The EORTC session which will be held within the programme of the ECCO2017 congress, will address the principles of the future of cancer clinical research and therapy.
www.eortc.org Contact EORTC Events Office: [email protected]
The EORTC session which will be held within the programme of the ECCO2017 congress
Current Challenges: Future Opportunities
Meet your European colleagues to discuss the
latest developments in oncology nursing.
Details at: www.cancernurse.eu
In collaboration with: www.ecco-org.eu
The European Oncology Nursing Society presents a one day dedicated cancer nursing programme
27 January 2017, Amsterdam Rai, The Netherlands
52 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 53ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
Twitter hashtag: #ECCOCongress
Accommodation
Amsterdam RAI Hotel Services has been appointed as the official local housing partner for ECCO2017 and is offering hotel accommodation for both groups and individuals.
For all accommodation queries and information, please contact: [email protected] or tel: +31 (0)20 549 1927.
We kindly ask you to contact the appointed local housing partner directly. The congress secretariat cannot provide accommodation-related information or handle any related requests.
Digital Programme
The ECCO2017 programme will be digital only:
• Get an accurate programme at all times, including any last-minute changes
• Create your personalised programme selection
• Find out quickly and easily where you need to go for your chosen session
• Lighten your load: no book to carry around
• Know that you are helping our environment: together we avoid massive paper consumption!
The digital programme is available:
• As a Searchable Programme on our website
• In our Mobile App
Browse and download at eccocongress.org
GENERAL INFORMATION
CONGRESS VENUE
Detailed information about the venue: www.rai.nl
Insurance
The organisers do not accept liability for individual medical, travel or personal insurance. Participants are strongly encouraged to make their own arrangements regarding health and travel insurance.
Language and Translation
The official language of the Congress is English. No simultaneous translation will be provided.
Lunch and Refreshments
Lunch or refreshments are not included as part of the registration fee.
Networking
ECCO2017 guarantees a wealth of networking opportunities. Our OncoHub which replaces the traditional exhibition hall is designed to promote maximum interaction among congress delegates. ECCO2017 is a unique opportunity to exchange ideas with representatives of all oncology professions as well as patient advocates, policy makers and industry. Meet them in the OncoHub, discuss hot topics in interactive sessions and connect with everyone through our dedicated online community platform.
Amsterdam RAIEuropaplein1078 AZ AmsterdamThe Netherlands
Accommodation reservation opens:
1st June 2016
Accommodation reservation deadline: 28th November 2016
Registration will open in April 2016.
Early Rate Deadline: Monday 27 June 2016
Early Rate Members 399
Early Rate Non Members 599
Early Rate Groups 599
Early Rate Junior Participants 175
Early Rate Emerging Economy 130
Early Rate Nursing Members 250
Early Rate Nursing Non Members 350
Early Rate Patient Advocates 125
Early Rate Payers (Medical insurance non for profit), HTAs, Regulators 150
Regular Rate Deadline: Monday 28 November 2016
Regular Rate Members 550
Regular Rate Non Members 750
Regular Rate Groups 750
Regular Rate Junior Participants 199
Regular Rate Nursing Members 355
Regular Rate Nursing Non Members 475
Regular Rate Patient Advocates 150
Regular Rate Payers (Medical insurance non for profit), HTAs, Regulators 175
Late Rate Deadline: until last congress day
Late Rate Members 899
Late Rate Non Members 1.099
Late Rate Junior Participants 220
Late Rate Nursing Members 460
Late Rate Nursing Non Members 585
Late Rate Patient Advocates 150
Late Rate Payers (Medical insurance non for profit), HTAs, Regulators 175
Society Day Programme
EONS, EORTC, ESO, ESTRO, SIOPE
ESSO 37 Congress Rates can viewed at eccocongress.org/registration
GENERAL INFORMATION – YOUR A TO Z TO ECCO2017
REGISTRATION WILL OPEN IN APRIL 2016Detailed information about how to register and the terms and conditions will be available http://www.eccocongress.org/registration
REGISTRATION FEES ARE THE FOLLOWING:
Primary Care Programme Day Rate 150
€
€
€
54 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 55ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
Secretariat:ECCO – the European CanCer OrganisationAvenue E. Mounier 83 B-1200 Brussels, BelgiumTel: +32(0) 2 775 02 01Website: eccocongress.org Hashtag: #ECCOCongress
Congress Dates27–30 January 2017
Detailed information about the venue: www.rai.nl
AccommodationFor all accommodation queries and information, please contact: [email protected] or tel: +31 (0)20 549 1927.
Registration Registration will open in April 2016.
Congress Venue Amsterdam RAIEuropaplein1078 AZ AmsterdamThe Netherlands
SUMMARY INDUSTRY CONTACT:
Bruno De ManPhone: +32 2 775 02 04Email: bruno.deman@ ecco-org.eu
Participants registered for the entire duration of the ECCO2017 Congress are entitled to one free public transport ticket giving access to public transport in Amsterdam throughout the event (transportation to and from the airport is not included).
Delegates are encouraged to use public transport as much as possible.
RAI Amsterdam is easy to reach by both public transport or by car and has ample parking facilities on and outside its site. RAI Amsterdam is situated 8 minutes from Amsterdam’s city centre and 15 minutes from Amsterdam Schiphol Airport.
TRANSPORTATION
INDUSTRY OPPORTUNITIES
Showcase your latest scientific data at ECCO2017 – European Cancer Congress, the multidisciplinary meeting for all cancer types, addressing all oncology disciplines and related healthcare professions.
ECCO2017 will have a direct impact on clinical practice and will gather thousands of oncologists from Europe and around the world. This is your chance to present your data before Europe’s unique multidisciplinary oncology platform.
The congress provides you with established, effective activities like Satellite Symposia and, at the same time, it offers you a wealth of innovative opportunities. Among those is our special OncoHub where delegates will meet to network and learn about new developments. You can also benefit from a wide range of advertising and sponsorship options.
We look forward to working with you to identify and secure the items best suited to your objectives for your participation at ECCO2017.
GENERAL INFORMATION
56 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org
eccocongress.orgCongress Secretariat:ECCO – the European CanCer Organisationecco-org.eu
Congress Venue:Amsterdam RAIThe Netherlands